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THE ONCOGENIC ROLE OF THE PROTEIN TYROSINE PHOSPHATASE 4A3 
(PTP4A3 OR PRL-3) IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA 
 
T-cell Acute Lymphoblastic Leukemia (T-ALL) is an aggressive blood cancer. 
There are no immunotherapies and few molecularly targeted therapeutics available for the 
treatment of this malignancy. The identification and characterization of genes and 
pathways that drive T-ALL progression is critical for the development of new therapies for 
T-ALL. The protein tyrosine phosphatase PTP4A3, also known as PRL-3, has been 
extensively reported to play a causative role in numerous cancers, including several types 
of blood malignancies. However, its role in T-ALL is not well defined.  
Here, we determined that the PRL-3 plays a critical role in T-ALL initiation and 
progression by promoting leukemia cell migration. PRL-3 is highly expressed in patient T-
ALL samples at both mRNA and protein levels compared to normal lymphocytes. Knock-
down of PRL-3 expression using short-hairpin RNA (shRNA) in human T-ALL cell lines 
significantly impeded T-ALL cell migration capacity in vitro and reduced their ability to 
engraft and proliferate in xenograft mouse models. Additionally, PRL-3 over-expression 
in a Myc-induced zebrafish T-ALL model significantly accelerated disease onset and 
shortened the time needed for cells to enter blood circulation. Reverse phase protein array 
(RPPA) and gene set enrichment analysis (GSEA) revealed that the SRC signaling pathway 
is affected by PRL-3. Immunoblot analyses validated that manipulation of PRL-3 
expression in T-ALL cells affected the SRC signaling pathway, which is directly involved 
in cell migration, although SRC was not a direct substrate of PRL-3. More importantly, T-
ALL cell growth and migration was inhibited by small molecule inhibition of PRL-3, 
suggesting that PRL-3 has potential as a therapeutic target in T-ALL.  
Finally, we identified a pool of PRL-3 interacting proteins in T-ALL using BioID-
based proximal labeling approach. Co-immunoprecipitation assays were used to validate a 
number of direct interacting partners of PRL-3, including LCK and CD3.  
Taken together, our study identifies PRL-3 as an oncogenic driver in T-ALL both 
in vitro and in vivo and provides a strong rationale for targeted therapies that interfere with 
PRL-3 function. We also identified PRL-3 interactomes in T-ALL, which lays foundation 
for future PRL-3 substrates study.  
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CHAPTER 1. T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA 
1.1 Introduction of T-cell Acute Lymphoblastic Leukemia 
Acute lymphoblastic leukemia, also known as ALL, is a type of blood cancer in 
which the bone marrow produces malignant and abnormal lymphocytes and fails to make 
enough normal blood cells, leading to common symptoms such as fever, infection, 
bruising, and bleeding. ALL is the most prevalent cancer among children, accounting for 
20% of all cancers diagnosed in people aged <20 years. There are >3,000 new cases each 
year in the United States. The overall incidence of pediatric ALL was 3.4 cases per 
100,000/year from 2001–2014 with the highest incidence peak in children aged 1–4 years 
(7.5/100,000)1. ALL also is one of the leading causes of death from cancer for children 
younger than 20 years old2. In adults, ALL is the second most common acute leukemia, 
with ~ 1300 new cases in the year 2016 in the United States1.  
Despite the great success achieved in the treatment of ALL in the last 5 decades, 
reflected by the enormous increase in survival rate, from less than 10% in the 1960s to 
about 90% today, there are still challenges with its treatment. One challenge comes from 
the short-and long-term toxicities due to the intensive chemotherapies. A study published 
in 2008 following 4,151 pediatric ALL survivors demonstrated that 65% of them suffered 
from at least one chronic condition and 21% reported severe medical conditions including 
death, even 25 years after diagnosis3. Those medical conditions include long-term 
neurocognitive deficits, neurologic dysfunction (stroke and peripheral neuropathies), 
neuroendocrine dysfunction (growth hormone deficiency and precocious puberty), 
metabolic abnormalities (obesity and metabolic syndrome), bone toxicity (osteonecrosis 
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and bone mineral density deficits), and cardiac damage. Survivors of ALL treated with 
cranial radiation therapy showed a highest risk for neurocognitive impairment4. 
Another main clinical challenge for ALL is relapse, which remains a major source 
of childhood cancer-associated mortality. A study following patients between 1988-2002 
showed that 20.5% of pediatric ALL patients experienced relapse. The 5-year survival rate 
after relapse is between 24.1% and 58.7%, depending on the site of relapse5. 
ALL arises from two different types of lymphocyte precursors, T and B lymphocyte 
precursors, and is correspondingly divided into two subtypes, T-ALL and B-ALL. T-ALL 
is less common than B-ALL, only accounting for about 15% of all pediatric ALL cases and 
25% of adult ALL cases5. However, T-ALL is a more aggressive subtype compared with 
B-ALL, reflected by a significantly lower 5-year survival rate, 81.6% compared with 
91.1% for B-ALL6. 
1.2 Current Approaches and Challenges for T-ALL 
1.2.1 Current Approaches for T-ALL Treatment 
Currently, the main treatment of ALL is typically using intensive multi-drug 
regimens, which typically includes 3 phases and lasts 2 to 3 years: induction therapy, 
consolidation (intensification) therapy and maintenance therapy. There are 8 main 
categories of antineoplastic agents used for childhood ALL (Table 1). 
The goal of induction therapy, which normally lasts 4-6 weeks, is to attain a 
remission where leukemia cannot be detected and no more symptoms in patients. The 
chemotherapy drugs used in induction therapy is a cocktail consisting of glucocorticoids, 
vincristine, L-asparaginase, and the optional use of anthracycline class according to the 
risk stratification. Features including initial white blood cell (WBC) count, age, 
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cytogenetics and ploidy, immunologic subtype, rapid and degree of cytoreduction are 
used to stratify ALL patients into 3 groups, standard, intermediate or high risk. Almost all 
patients can attain remission after induction phase, however, relapse is prevalent without 
intensification therapy2,7.  
The consolidation (intensification) phase, as its name suggests, is to consolidate 
remission and also prevent spreading of leukemia to the central nervous system. The 
consolidation phase lasts 6 to 8 months and often uses more intensive chemotherapy 
combinations. The drugs used in this phase include methotrexate, a glucocorticoid, 
vincristine, L-asparaginase, anthracycline class, 6-mercaptopurine (6-MP), etoposide, 
cyclophosphamide, and cytarabine, but regimens vary among cancer centers2,7.  
 Maintenance therapy is prolonged, lasting 18 to 30 months. Daily 6-
mercaptopurine (6-MP) and weekly methotrexate, often along with vincristine and a 
steroid, is generally used in this phase2,7. 
1.2.2 Challenges for T-ALL 
T-ALL is a high-risk subgroup of pediatric ALL compared to B-ALL, and T-ALL 
patients are typically classified into high-risk arms of risk-stratified regimens and are 
subjected to more intensive treatment but still have higher risk of induction failure and 
early relapse, compared to B-ALL patient8,9. A study followed 1,041 patients with 
induction failure out of 44,017 patients and identified that the 10-year survival rate was 
only ~28% for T-ALL patients compared with 41% for B-ALL6. Adult T-ALL has only 
about 50% survival at 5 years1, which is comparable to adult B-ALL4. Central nerve system 
(CNS) involvement, a major clinical problem of ALL, is also higher in T-ALL patients 
compared with B-ALL4.The patients with CNS involvement require pre-emptive CNS-
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directed intrathecal chemotherapy and cranial radiation therapy. Meanwhile, the current 
intensive multi-chemo regimens are non-targeted, often causing short- and longer-term 
toxicities.  
The prognosis of T-ALL relapsed patients is dismal. Only 23.0% of T-ALL relapse 
patients achieved 5-year survival, significantly lower compared with that of B-ALL relapse 
patients5. A major reason for this is that the development of new treatments for relapsed T-
ALL lags behind that for relapsed B-ALL, which has benefited from several new targeted 
therapy drugs, including imatinib10, inotuzumab ozogamicin11, blinatumomab11, and CAR-
T Cell therapy12. The only agent FDA-approved specifically for relapsed T-ALL is 
nelarabine, which is a purine nucleoside analog and was approved in 2005. Several Phase 
II studies using nelarabine as the single agent to teat pediatric T-ALL patients only 
achieved short complete remission, between 31%-47%. Neurotoxicity of nelarabine was 
also observed in clinical trial, including seizures, neuropathy, and mental status changes4. 
In conclusion, lack of less toxic, targeted therapies for T-ALL severely affects the 
prognosis and quality of life of the long-term survivors, most of which are children. No 
effective salvage treatment for relapsed T-ALL leads to dismal outcomes in these patients. 
Therefore, novel therapies for T-ALL are critically needed. In order to develop more 
effective drugs to improve the outcome of relapsed T-ALL patients and to identify targeted 
therapies to reduce the toxicity of current chemo-regimens, we need to identify and 
characterize new drivers of T-ALL initiation and progression.  
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1.2.3 Development of Targeted Therapies for T-ALL. 
Recent close collaboration between clinical groups and research labs have 
identified that one of the hallmarks of ALL is genetic alterations which drive the initiation 
and progression of the disease1. Tremendous efforts are being put to characterize those 
genetic alterations, which may help to identify risk stratification, refine treatment regimens, 
and develop novel targeted therapies, thus ultimately improving patient prognosis. 
The most common recurrent genetic alterations in T-ALL are chromosomal 
rearrangements, which are detected in up to 70% of T-ALL cases and commonly involve 
T-cell receptor (TCR) genes, including TRA and TRD at 14q11, TRB at 7q34 and TRG at 
7p14. These rearrangements frequently dysregulate a number of transcription factors and 
related genes, including MYC (MYC Proto-Oncogene), TAL1/2 (T-cell acute lymphocytic 
leukemia protein 1/2), LYL1 (lymphoblastic leukemia derived sequence 1), BHLHB1 (basic 
helix-loop-helix transcription factor B1), LMO1/2 (LIM-only domain proteins 1/2), 
TLX1/3 (T cell leukemia homeobox 1/3), NOTCH1(Notch receptor 1), CCND2 (G1/S-
specific cyclin-D2), and LCK (lymphocyte-specific protein tyrosine kinase).These 
transcription factors are commonly involved in normal haemetopoiesis, T-cell self-renewal 
and development. Their dysregulation leads to leukemogenesis and T-cell malignancies2,9. 
The rapid development of Next Generation Sequencing (NGS) allowed 
identification of a large set of mutations in T-ALL, including NOTCH1, FBXW7 (F-
box/WD repeat-containing protein 7), CDKN2A/2B (cyclin-dependent kinase Inhibitor), 
BCL11B (B-cell lymphoma/leukemia 11B), JAK1 (Janus kinase 1), PTPN2 (Tyrosine-
protein phosphatase non-receptor type 2), IL7R (Interleukin-7 receptor) and PHF6 (plant 
6 
homeodomain (PHD)-like finger). Among them, NOTCH1, FBXW7 and CDKN2A/2B are 
the most prevalent sites of mutation.  
1.2.3.1 Targeting NOTCH1 Signaling Pathway for T-ALL 
NOTCH1 activating mutations occur in >50% of T-ALL cases and FBXW7 
mutations account for 10% to 15% of T-ALL cases, representing the most frequent 
oncogenic pathway across all subtypes of T-ALL3. NOTCH proteins, including NOTCH1-
4, are a family of type-1 transmembrane proteins that regulate cell-to-cell communication. 
NOTCH proteins play a major role in T-cell lineage commitment. NOTCH1 has a major 
role in regulating different intrathymic T-cell development stages. NOTCH proteins must 
to be cleaved upon activation. The first cleavage of Notch protein is processed by Furin 
before it is expressed on the cell surface as a heterodimer. ADAM 10, a metalloprotease, 
and γ-secretase carry out the additional two cleavages, which ultimately generate active 
intracellular domain of NOTCH (NICD). NICD is a transcription factor that can translocate 
into the nucleus and regulates differentiation and proliferation through the activation of 
various target genes. FBXW7 is part of the E3 ubiquitin ligase complex and controls 
proteasome-mediated degradation of various proteins including NOTCH. Therefore, both 
NOTCH1 activating mutations and inactivating mutations of FBXW7 lead to stabilization 
of NICD in the nucleus, resulting in activation of oncogenic NOTCH1 signaling13,14. 
As NOTCH1 hyper-activation is prevalent in T-ALL, great efforts have been put to 
investigate the efficacy of anti-NOTCH1 antibody and γ-secretase inhibitors (GSIs) that 
block NOTCH1 activation in the treatment of T-ALL. The anti-leukemic effects of anti-
NOTCH1 antibody have been demonstrated both in vitro and in vivo against T-ALL cell 
lines, and also in xenotransplantation of primary T-ALL patient samples15,16. For example, 
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anti-NOTCH1 monoclonal antibody significantly delayed xenotransplantation of T-ALL 
patient samples harboring NOTHC1 mutations, where the anti-tumor effects came from 
increased apoptosis, decreased proliferation and altered cell metabolism. Interestingly, 
incorporation of dexamethasone significantly enhanced efficacy of anti-NOTCH1 
monoclonal antibody therapy16. 
Another strategy of inhibiting aberrant NOTCH1 signaling for the treatment of 
leukemia is to use γ-secretase inhibitors (GSIs). Both in vitro and in vivo pre-clinical 
studies have demonstrated anti-leukemic effects of GSIs17–21. GSIs treatment resulted in 
G1 cell cycle arrest, increased apoptosis, decreased cell size and leukemic-initiating cell 
activity. However, phase I clinical trials showed very limited therapeutic activity to date. 
In addition, there are severe gastrointestinal toxicities of GSIs observed in the clinical trials, 
which also restricts the clinical application of GSIs22,23.  
1.2.3.2 Targeting Increased Kinase Activity for T-ALL 
Although CDKN2A/2B is one of the two mutations present in >50% T-ALL except 
NOTCH24, it is challenging to target it for T-ALL treatment. CDKN2A/2B encode the 
INK4/ARF (Inhibitors of CDK4) family of tumor suppressors and cell-cycle regulators and 
it is difficult to restore the activity of a deleted tumor suppressor gene. 
Another aberrant phenotype in a subset of T-ALL that can be harnessed to develop 
targeted therapies is increased kinase activity, including PI3K/PTEN/AKT pathway, ABL1 
and JAT/STAT pathway. Mutation of PI3K/PTEN/AKT pathway was detected in ~50% of 
pediatric T-ALL25. Phase I clinical trial of buparlisib, a pan-class I PI3K inhibitor, has been 
finished and showed only moderate efficacy in advanced leukemia. Another PI3K 
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inhibitor, dactolisib, is currently under Phase I clinical trial for use in relapsed or refractory 
acute luekmia25. 
NUP214 encodes nucleoporin 214, a protein required for cell cycle and 
nucleocytoplasmic transport. ABL1 is a proto-oncogene encoding a protein tyrosine kinase 
ABL1, which is involved in process of cell differentiation, division, and adhesion. The 
fusion of NUP214 to ABL1 cannot activate the ABL1 kinase26. While episomal 
amplification of NUP214-ABL1 resulted in oncogenic hyperactivation of ABL1. The 
NUP214-ABL1 fusion transcript has been detected in a subset of T-ALL patients, varying 
in the range of between 5.8% to 10%27. Preclinical studies showed that kinase inhibitors, 
including imatinib, nilotinib, and dasatinib, were effective against NUP214-ABL1 positive 
cell lines or mouse xenograft models. There are also case reports of NUP214-ABL1 positive 
T-ALL patients responding to imatinib/dasatinib treatment28,29. Further evaluation of ABL 
kinase inhibitors against a larger cohort of NUP214-ABL1 positive T-ALL patients is 
needed. 
JAK/STAT inhibition may also have therapeutic potential for T-ALL. The 
activating mutations in JAK/STAT pathway, including mutations in IL7/IL7R, JAK1/3, 
and/or STAT5 are detected in 20% to 30% T-ALL cases24. JAK1/2 inhibitor ruxolitinib 
showed efficacy against T-ALL patient-derived murine xenograft models. Surprisingly, the 
efficacy of ruxolitinib is not dependent on JAK/STAT pathway mutations30. Addition of 
ruxolitinib or removing IL7 to inhibit JAK/STAT pathway overcame glucocorticoid 
resistance in a subset of T-ALL in patient derived xenograft models31. 
Although great efforts have been put in developing targeted therapies for T-ALL, 
it still lags behind that of B-ALL and other types of leukemias. T-ALL patient has not 
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received benefits from the above discussed target therapies. The identification and 
characterization of new drivers for T-ALL is critically needed for this purpose. Contrarily 
to the protein tyrosine kinases, which are the most successful drug target and achieved 
great clinical success, protein tyrosine phosphatases are underexplored as cancer 
therapeutic targets. The past two decades study about protein tyrosine phosphatases 
demonstrated potential of them as cancer targets and are receiving arising attention32,33.
Table 1 Chemotherapeutic Drugs for Childhood Leukemia 






Apoptosis by binding to intracellular 
steroid receptors Throughout 
Vinca alkaloids Vincristine Sulfate Vincristine Sulfate Liposome Disruption of mitotic spindle Throughout 
L-Asparaginase 
Calaspargase pegol 
Asparaginase Erwinia Dhrysanthemi 
Erwinase 
Pegaspargase 





DNA intercalation Inhibition of topo-
isomerase II function 
Induction and 
intensification 
Alkylating agents Cyclophosphamide Inter-strand DNA cross-links Intensification 
Methotrexate methotrexate Anti-folate Maintenance CNS-directed therapy 
Purine Analogs 6-thioguanine 
6-mercaptopurine Inhibition of DNA synthesis Maintenance 
Pyrimidine Analog Cytarabine Inhibition of DNA synthesis Intensification 
Epipodophyllotoxins Etoposide Interferes with topo II re-ligation of double-stranded DNA breaks Intensification 
Adapted from Table 7.14
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CHAPTER 2. PRL-3 IS AN ONCOGENIC PHOSPHATASE 
2.1 Phosphatases are Underexplored Drug Targets 
Protein tyrosine phosphatases (PTPs) are a large family of enzymes that catalyze 
the removal of phosphate groups that are attached to tyrosine residues on substrates. Protein 
tyrosine kinases (PTKs), on the contrary, are the enzymes that transfer a phosphate group 
to the tyrosine residue on corresponding substrates. PTPs cooperate with PTKs to precisely 
maintain appropriate protein phosphorylation and have important roles in modulating the 
strength and duration of signaling events, which is critical for normal cellular functions, 
including cell survival, apoptosis, proliferation, migration as well as differentiation32.  
The aberrant phosphorylation of proteins is implicated in many human diseases, 
including cancer, inflammatory diseases, diabetes/obesity, central nervous system (CNS) 
disorders, and cardiovascular diseases32. Since over-activation of PTKs is a common 
feature of many types of cancer, PTKs are one of the most intensively explored drug targets 
for cancer treatment. As a result, several PTK inhibitors have achieved clinical success and 
become the standard of care in several types of cancer, including afatinib for non-small-
cell lung cancer34 and imatinib for chronic myeloid leukemia35.  
However, until recently, PTPs have not received similar attention as therapeutic 
targets, primarily due to misconceptions that phosphatases are only tumor suppressors or 
that they lack regulatory roles in disease32,33. Nonetheless, accumulating evidence has 
shown that phosphatases are suitable therapeutic targets in cancer. For example, Protein 
Tyrosine Phosphatase 1B (PTP1B) is reported to play a tumor-promoting role in prostate 
and colorectal cancer36, and high PTP1B expression is associated with poor prognosis in 
colorectal cancer patients36,37. Additionally, protein tyrosine phosphatase SHP2 (Src 
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homology region 2 (SH2)-containing protein tyrosine phosphatase 2) increases tumor 
progression and maintains tumor-initiating cells in breast cancer38,39. To date, more than 
30 potential oncogenic phosphatases have been identified, and are currently being explored 
as drug targets in cancer therapy. Consequently, the interest in exploring phosphatases as 
drug targets to treat cancer has risen sharply in the last decade. 
2.2 Introduction of PRLs 
PRLs (Phosphatase of Regenerating Liver), also known as the Protein Tyrosine 
Phosphatase 4A (PTP4A) family, are dual-specificity phosphatases, which can act on 
tyrosine residues and serine/threonine residues to remove phosphate40. PRL-1 was the first 
identified PRL and discovered in 1991 as one of the immediate-early genes up-regulated 
in regenerating rat liver after partial hepatectomy41. Later, the sequence analysis of PRL-1 
identified a PTP signature motif, Valine-Histidine-Cysteine-(any amino acid)5-Arginine 
(VHC(X)5R), but with no homology to other PTPs outside this signature sequence. In vitro 
phosphatase assays using a generic DiFMUP substrate demonstrated that PRL-1 had 
phosphatase activity. Therefore, PRL-1 emerged the first in a new class of PTPs42. 
Later, PRL-2 and PRL-3 were identified based on a sequence homology search in 
the Murine Expressed Sequence Tags database43. In humans, PRL-1 and PRL-2 are most 
similar in amino sequence, sharing 87% homology, while PRL-1 and PRL-3 exhibit 79% 
homology, and PRL-2 and PRL-3 are 76% homologous (Figure 1)44,45.  
The genes that encode PRL-1, PRL-2, and PRL-3 are found on chromosome 6q12, 
1p35, and 8q24.3, respectively. PRL-1 and PRL-2 mRNA expression was ubiquitously 
detected across almost all normal human tissues and major organ systems46, while PRL-3 
expression was detected primarily in the heart, skeletal muscle, vasculature, and the brain43. 
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PRL proteins have a small molecular weight, at 22kDa, with 173 amino acids in 
PRL-1 and PRL-3, and 167 amino acids in PRL-244.  Sequence alignment of PRL-1, PRL-
2, and PRL-3 shows that they all carry the conserved catalytic PTP motif  
VHC (X)5R, also known as a P-loop, a WPFDD (Tryptophan-Proline-Phenylalanine-
Aspartate-Aspartate) loop, polybasic region, and CAAX (where C represents Cysteine, A 
represents aliphatic amino acid and X refers to any amino acid) prenylation motif (Figure
1), the functions of which are highlighted below.
Similar to other PTPs, the cysteine residue in the P-loop (Cys104 in PRL-1 and 
PRL-3 or Cys101 in PRL-2) acts as a nucleophile during phosphorylation, forming a 
thiophosphoryl enzyme intermediate (Figure 2). C104S mutation was shown to abolish 
PRL enzymatic activity in vitro 47,48and its metastatic activity in a xenograft mice 
model49,50. The arginine residue in the P-loop (Arg110 in PRL-1 and PRL-3 or Arg107 in 
PRL-2) facilitates substrate binding by interacting with the phospho-tyrosine in substrates. 
An R110A mutation in PRL-3 completely abolished its phosphatase activity in vitro48. The 
second aspartate residue in the WPFDD loop (Asp72 in PRL-1 and PRL-3 or Asp69 in 
PRL-2) acts as a general acid by donating a proton to the substrate in the first step and a 
general base by activating a water molecule in the second step, promoting formation and 
hydrolysis of the enzyme intermediate (Figure 2). D72A mutation has been reported to 
decrease PRL catalytic activity49,51. Therefore, both the P-loop and WPFDD loop are 
critical for PRL phosphatase activity.   
The CAAX motif, also known as a prenylation motif, at C-terminus of PRLs is 
unique to PRLs and not found in other PTPs. This feature is important for PRL 
subcellularlocalization51. The polybasic region preceding CAAX motif (between residues 
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151 and 161 in PRL-1 and PRL-3 or between 148 and 158 in PRL-2) facilitates PRLs 
binding to the membrane by interacting with negatively charged phospholipids in the 
membrane40,52. Overexpressed N-terminal Myc-tagged PRL-1, PRL-2, and PRL-3 in CHO 
cells were all shown to localize on the plasma membrane and early endosome using 
immunofluorescent microscopy and electron microscope immunogold labeling. Inhibition 
of prenylation of PRL-1, PRL-2, and PRL-3 using selective farnesyltransferase inhibitor 
FTT-277 led to re-distribution of all the PRLs into the nucleus. Similarly, the truncated 
PRL-2 without the CAAX motif was localized in the nucleus. The re-distribution of PRLs 
between plasma membrane and nucleus may play a role in functional regulation of PRLs51. 
The alanine residue following the arginine residue in the P-loop also differentiates 
PRLs from other PTPs. Serine or threonine, which is believed to play an important role in 
the hydrolysis of the phosphoenzyme intermediate, occupies this position in most PTPs. 
Consistently, a mutation of PRL-1 that replaces this alanine with a serine (A111S) showed 
increased activity toward synthetic substrate52. The presence of alanine instead of 
serine/threonine in PRLs may therefore contribute partially to the low phosphatase activity 
of PRLs in vitro. The residues in P-loop of PRL-3, Val105-Ala-Gly-Leu-Gly109, is highly 
hydrophobic compared with other phosphatases47, which suggests different substrate 
selectivity. This feature implies the possibility of developing hydrophobic high affinity 
competitive PRL inhibitors with better cell permeability, as other PTP competitive 
inhibitors are more likely to be highly charged due to charged active site.  
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2.3 PRL-3 and Cancer 
2.3.1  Oncogenic Role of PRL-3 
PRLs are largely considered oncogenic phosphatases that play critical roles in 
tumor progression and metastasis across a variety of human cancers. PRL-3 is the best 
studied PRL and extensively reported as a biomarker of tumor progression and metastasis. 
PRL-3 expression was elevated in tumor tissues, compared with healthy tissues, or in 
advanced versus early stage tumors, spanning colorectal53,54, breast55,56, gastric57, 
ovarian58, liver59, prostate60, lung61 cancers, AML (acute myeloid leukemia)62,63 and B-
ALL ( B-cell acute lymphoblastic leukemia)64. Importantly, high PRL-3 expression was 
often correlated with poor prognosis in patients with colon65, breast55,56,66, gastric67,68, 
liver59, lung61, ovarian cancers69 and AML62, which suggests a causative role for PRL-3 in 
cancer progression. A direct contributing role for PRL-3 in cancer has been demonstrated 
by over-expression and knockdown of PRL-3 in normal or cancer cell lines. For example, 
human cell lines transfected with PRL-3, spanning human melanoma, breast, lung, and 
colorectal cancer, exhibited increased oncogenic properties compared to control, including 
increased motility, migration, invasion, and proliferation in vitro. PRL-3 expression 
significantly enhanced tumor progression and metastasis after transplantation of the 
transfected cells in mice49. Conversely, PRL-3 knock-down led to decreased cell 
proliferation, migration, and invasion of melanoma, gastric, ovarian, lung cancer cell line 
in vitro and inhibited primary tumor proliferation and metastasis in mouse cancer or 
xenograft models70.  
The role of PRL-3 in cancer is further demonstrated in a Prl-3 knockout mouse 
model71. In this model, Prl-3 deletion protected mice from developing colon cancer 
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induced by azoxymethane and dextran sodium sulfate. They also observed increased Prl-3 
mRNA expression in the colon tissues of Prl-3 wildtype mice as early as 8 hours after 
azoxymethane treatment, suggesting a correlation of Prl-3 with tumor initiation.  
Consistent with the findings in PRL-3 knockout mice, there is additional evidence 
that PRL-3 may also play an important role in the tumor angiogenesis. For example, PRL-
3 mRNA was detected in endothelial cells within colon cancer metastasis72and was 
increased 6-fold in breast tumor endothelium compared to surrounding epithelial cells73. 
Overexpression of PRL-3 in human microvascular endothelial cells (HMVEC) in vitro 
enhanced endothelial tube formation74 and endothelial cell migration73. Additionally, PRL-
3 knock-out in mice led to decreased micro-vessel density in colon tumor tissues compared 
with wild type controls. Furthermore, vascular cells isolated from PRL-3-null mice were 
less invasive and migratory in vitro, compared with wild type cells. Further studies are 
needed to definitively link PRL-3 to angiogenesis in the cancer setting, and the role of 
PRL-3 in other migratory cells within the tumor microenvironment, such as fibroblasts and 
immune cells, remains to be defined.  
In conclusion, these studies demonstrated that elevated PRL-3 expression is a 
common feature across various cancer types, suggesting that PRL-3 can serve as a 
biomarker of tumor progression and a potential predictor of patient prognosis. In addition, 
the causative role of PRL-3 in tumor progression implies that PRL-3 holds the potential for 
cancer treatment.  
2.3.2 PRL-3 Substrates and Signaling Pathways Mediated by PRL-3  
The substrates study of phosphatase is generally challenging as the interaction 
between phosphatase and its substrate is weak and transient, making isolation of the 
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phosphatase-substrate complex difficult. This challenge is reflected by the fact that there 
are only 336 protein substrates and 83 non-protein substrates identified for 241 human 
phosphatases according to DEPOD database (http://depod.bioss.uni-freiburg.de/br_s.php) 
as of February 22, 2020. In contrast, there are 10257 protein substrates for 518 protein 
kinases according to the RegPhos (http://140.138.144.141/~RegPhos/index.php). It is 
even more challenging to identify PRL substrates, as the catalytic pocket of PRLs are 
shallower and wider compared to other PTPs51. Consequently, only Keratin 8 and integrin 
β1 showed evidence as PRL-3 direct substrates. Nonetheless, a few PRL-3 interacting 
proteins, not necessarily direct targets, have been reported (Table 2). 
Keratin 8 has been reported as a PRL-3 substrate, which is identified by 
differential phospho-protein examination using 2D-PAGE combined with MS approach 
in SW480 colorectal cancer cells that overexpressed wild type or C104S mutant PRL-3. 
Co-immunoprecipitation and co-localization assay validated that dephosphorylation of 
keratin 8 at S73 and S431 by PRL-3 is a direct interaction. Importantly, IHC staining of 
CRC patient samples showed that PRL-3 high expression associated with reduced 
phosphorylation of keratin 8, particularly at the invasive front and in the liver 
metastasis75. However, due to the limited samples examined, it is not known that whether 
this correlation is prevalent or not. And how the dephosphorylation of keratin 8 regulated 
by PRL-3 contributes to colorectal cancer is not studied.  
Integrin β1, one member of integrin family and critical player in cell adhesion 
regulation, is another reported PRL-3 substrate. Overexpression of PRL-3 in HEK293 
(Human embryonic kidney 293) cells down regulated phosphorylation of integrin β1 while 
knockdown of PRL-3 increased phosphorylation of integrin β176. Similar finding was 
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identified by the same group in human colon cancer LoVo cells, which also showed that 
PRL-3 is physically associated with integrin β1 in a co-IP assay, suggesting that integrin 
β1 is a direct substrate of PRL-3. Importantly, the enhanced cell motility and invasion by 
PRL-3 is abolished by depletion of integrin β1 in LoVo cells. In addition, PRL-3 mediated 
metastasis of colon cancer in nude mice was also inhibited by knockdown of integrin β177. 
The mechanistic study showed that PRL-3 overexpression activates ERK 1/2 while PRL-
3 knockdown inhibits ERK 1/2 pathway. However, the exact tyrosine residues in integrin 
β1 that PRL-3 acts on was not reported in this study and how phosphorylation of integrin 
β1 is connected to ERK ½ pathways needs further study76,77. 
Besides keratin 8 and integrin β1, there are several other suggested PRL-3 
substrates, but no strong evidence as PRL-3 direct substrates (Table 2). For example, 
stathmin78, an important protein involved in the regulation of the microtube cytoskeleton 
and CDH2279, one member of cadherin family, have been shown to be associated with 
PRL-3 in multiple CRC (colorectal colon cancer) cell lines and /or primary CRC tissues 
by Co-IP and co-localization assay. In addition, the expression of stathmin or CDH22 is 
regulated by PRL-3. Similarly, Integrin α1 was identified as a PRL-3 interacting protein 
using yeast two-hybrid system and validated by co-IP in COS-7 monkey fibroblast cells 
that overexpress both PRL-3 and 76. However, the phosphorylation regulation of 
stathmin, CDH22 or integrin α1 by PRL-3 was not reported, therefore whether stathmin, 
CDH22 or integrin α1 are direct substrates of phosphatase PRL-3 needs further 
investigation.  
Ezrin, a member of ERM family (ezrin/radixin/moesin)80, elongation factor 281, 
phosphoinositide PI (4,5) P2 and PI (3,4,5) P382 are also suggested PRL-3 substrates. 
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There is evidence to show that PRL-3 regulates the phosphorylation of these suggested 
substrates, however, there was insufficient evidence to conclude the direct interaction 
between them and PRL-3.  
CNNM, cyclin M family proteins and known as magnesium transporters, are 
identified as PRL-3 interacting proteins. The reciprocal Co-IP experiments in COS-7 and 
HEK293 cells demonstrated that PRL-3 is physically associated with CNNM1/2/3/4. The 
binding of PRL-3 to CNNM blocks the efflux of Mg2+ and consequently increase 
intracellular Mg2+concentration, which is reported to relate to tumorigenesis and tumor 
progression83.The PRL-3-CNNM3 complex structure resolved by crystallography 
provides molecular evidence for the interaction of PRL-3 and the CNNM family, which 
showed that PRL-3 is a pseudophosphatase as PRL-3 does not alter the phosphorylation 
of CNNM, though48.  
In order to understand the molecular mechanisms of how PRL-3 contributes to 
tumor initiation and progression, extensive studies have examined the signaling pathways 
affected by PRL-3. An unbiased mass-spectrometry-based approach was used to examine 
protein tyrosine phosphorylation related signaling networks affected by PRL-3 
overexpression in Human Embryonic Kidney (HEK) cells, and identified an extensive 
signal transduction network downstream of PDGF(α/β)-, Eph (A2/B3/B4)-, and Integrin 
(β1/β5)-receptors, including SRC, Rho-family GTPase, PI3K/Akt, STAT and ERK 
pathway activation84. These finding are corroborated in various cell models by different 
labs (Table 3).  
Rho family GTPases are a subfamily of the Ras superfamily and are key 
regulators of tumor cell motility and invasion via regulation of the actin cytoskeleton. 
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Overexpression of Rho family GTPases has been demonstrated in multiple cancer 
types85.  
Overexpression of PRL-3 in colorectal cancer cells activates RhoC86. Blocking 
PRL-3 in A549 lung cancer cells with an anti-PRL-3 antibody inhibits RhoA/C activity, 
leading to decreased cell migration and invasiveness61. PRL-3 physically associates with 
Arf1 (ADP-ribosylation factor 1), another small GTPase, and overexpression of PRL-3 in 
Hela cells activates Arf1, which is required for PRL-3 mediated cell migration87.  
PTEN/PI3K/AKT is an important pathway involved in multiple biological 
processes including cell proliferation, survival, apoptosis and metabolism. 
Overexpression of PRL-3 in Hela and DLD-1 cancer cells reduce expression of PTEN, a 
negative regulator of PI3K/AKT pathway, and consequently activates PI3K/AKT 
pathway while overexpression of a phosphatase dead mutant PRL-3 C104S 
overexpression did not88. The activation of the PI3K/AKT pathway promotes EMT 
(epithelial-mesenchymal transition), reflected by up-regulation of mesenchymal markers, 
such as fibronectin and Snail, and down-regulation of epithelial markers including E-
cadherin, γ-catenin and integrin β3. Interestingly, a study using MEFs (mouse embryonic 
fibroblasts) showed that PRL-3 overexpression induces cell cycle arrest via inhibition of 
PI3K/AKT pathway, which is not recapitulated in RKO colon cancer and U2OS 
osteosarcoma cells89.  
Aberrant activation of Src, a non-receptor kinase, occurs in a large fraction of 
cancers and plays a prominent role in cell migration and metastasis90. Ectopic expression 
of PRL-3 in HEK293 activated the Src pathway, reflected by decreased phosphorylation 
of Y527, which is an inhibitory phosphorylation site. However, Src was not a direct 
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substrate of PRL-3, instead, decreased Y527 phosphorylation occurred via PRL-3 
mediated down-regulation of Csk, which is a kinase responsible for Src Y527 
phosphorylation. Activation of the Src pathway leads to downstream activation of 
ERK1/2, STAT3, and p130Cas, which consequently promotes cell invasion, proliferation, 
and transformation. In addition, Src activation and Csk down-regulation are more 
significant in colon cancer cells that have higher PRL-3 expression, compared to lines 
with lower PRL-391. A study in B-ALL (acute lymphoblastic leukemia) cells 
demonstrated that PRL-3 knockdown inhibits Src pathway via decreasing 
phosphorylation of Y416, an activating phosphorylation site in Src. Src activation, 
together with FAK activation, regulates B-ALL cells adhesion and migration.  
In conclusion, PRL-3 is involved in a wide range of signaling pathways, which 
explains its oncogenic role, including cell migration, invasion, cell survival, apoptosis 
and proliferation. However, since PRL-3 substrates are largely unknown, we do not know 
what signaling pathways are directed regulated by PRL-3 and whether this regulation is 
dependent on its phosphatase activity. And most of the studies of PRL-3 discussed here 
were performed in solid tumors and there is no study to define its role in T-ALL, it would 
be informative to examine the oncogenic role and substrate of PRL-3 in T-ALL.  
2.4 Oncogenic PRL-1 and PRL-2 
Similar to PRL-3, both PRL-1 and PRL-2 are reported to have oncogenic roles in 
cancer, but these are less well defined. High PRL-1 expression was observed in cervical92, 
gastric cancers93and intrahepatic cholangiocarcinoma94. PRL-1 expression was correlated 
with poor patient prognosis in hepatocellular carcinoma95 and prostate cancer96. PRL-2 
expression was significantly increased in breast cancer93 and hepatocellular carcinomas97. 
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Inconsistently, in situ hybridization and immunohistochemistry showed that PRL-1 
expression was lower in ovarian, breast, and lung cancers and PRL-2 was significantly 
down-regulated in kidney carcinomas compared to normal tissue93.  However, the number 
of cases examined in this study was limited, and further research needed to validate the 
expression level of PRL-1 and PRL-2 in these cancer types. 
Studies of PRL-1 or PRL-2 over-expression or knockdown in cell lines show that 
PRL1/2 may have similar functions as PRL-3. For example, PRL-1 overexpression in 
Chinese Hamster Ovary (CHO) cells led to increased cell motility and invasiveness in vitro. 
The injection of those cells in nude mice induced lung tumor and liver metastasis; similar 
to the effects of PRL-3 overexpression in CHO cells98. The D27 hamster pancreatic ductal 
epithelial cells that ectopically overexpress PRL-1 or PRL-2 showed loss of contact 
inhibition in vitro and induced tumor growth in nude mice99. Different mouse mammary 
tumor–derived cell lines that overexpress PRL-2 showed increased anchorage-independent 
growth and cell migration. In addition, injection of DB-7 mammary cancer cells with PRL-
2 overexpression into the mouse mammary fat pad increase tumor growth100. Finally, PRL-
2 knock-down reduced the anchorage-independent growth and cell migration of human 
metastatic MDA-MB-231 breast cancer cells and reduced the cell migration and invasion 
of human A549 lung cancer cells, which can be rescued by co-transfecting an siRNA 
resistant PRL-2. 
2.5 Therapeutic Potential of PRL-3 in Cancer 
As the contributing role of PRLs, especially PRL-3, in tumor progression and 
metastases is now widely accepted, there has been great interest in developing specific PRL 
inhibitors as novel anti-cancer reagents. However, the conservative active site of PRLs with 
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other PTPs and the high percentage of identical primary sequence among PRLs present 
obstacles for developing small molecules that specifically target the PRL44. Consequently, 
the currently available PRL inhibitors have low selectivity, exhibiting inhibitory effects 
against other PTPs or all three PRLs (Table 4). As several PTPs, such as PTEN, are well 
known as tumor suppressors, it is critical to specifically target the oncogenic PRLs while 
sparing the tumor suppressing PTPs. Table 4 describes the currently available PRL 
inhibitors, which were identified or developed via high-throughput screening, virtual 
screening and/or SAR studies, and natural product screening. 
A high-throughput screen of the Roche chemical library for molecules that inhibit 
PRL phosphatase activity against a peptide substrate identified thienopyridone, which 
showed selectivity for PRLs over 11 other phosphatases, including tyrosine phosphatases 
and dual-specificity phosphatases such as PTP1B, SHP2, and CD45101. Thienopyridone 
was shown to significantly inhibit tumor cell anchorage-independent growth in soft agar 
and migration and induce anoikis via induction of the p130Cas cleavage in a p53-
independent manner101. A structural-activity-relationship (SAR) study of thienopyridone 
aiming to increase its stability and reduce its potential toxicity led to the development of 
JMS-053 (iminothienopyridinedione 13), which is a photooxygenation product of 
thienopyridone and showed a 10-fold increase in potency to inhibit PRLs compared to 
thienopyridone102,103. JMS-053 is a reversible and noncompetitive inhibitor of PRL-3 
when using the 6,8-difluoro-4-methyl-umbelliferyl phosphate (DiFMUP) substrate. The 
specificity test of JMS-053 against a panel of 25 other phosphatases, including receptor-
like PTPs, cytosolic PTPs, and dual specificity phosphatases, and 50 kinases showed that 
it is highly specific for the PRL family. The anti-tumor activity of JMS-053 has been 
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demonstrated in ovarian cancer in vitro and in vivo. JMS-053 rescued microvascular 
barrier function of endothelia cells, which was dysregulated when exposed to vascular 
endothelial growth factor or lipopolysaccharide. JMS-053 inhibited cell proliferation, 
migration and spheroid growth of ovarian cancer cells. Importantly, JMS-053 exhibits anti-
tumor activity on drug resistant ovarian cancer in a murine xenograft model at 
concentration as low as 0.1μM. In addition, the anti-tumor activity of JMS-053 was 
demonstrated on colon cancer and breast cancer cells in a three-dimensional spheroid 
assay104.  
 While JMS-053 is the most potent and specific PRL inhibitor developed, neither 
thienopyridone nor JMS-053 show specificity among the three PRLS. Although these 
compounds may still be beneficial, since all PRLs appear to have oncogenic effects and it 
may not be necessary to selectively target individual PRLs, until the normal functions of 
PRLs are known, it may be difficult to bring these compounds to the clinic. 
The small molecule PRL inhibitors that have been identified to date have no 
selectivity for the different PRLs, which is likely due to the extremely high degree of 
sequence identity among them. A different but promising strategy to specifically target 
different PRLs is the use of antibodies although intracellular proteins are generally 
considered not targetable by antibodies. This convention was challenged by a study where  
PRL-1 and PRL-3 mouse or rabbit antibodies have been developed that can specifically 
block the lung metastasis of xeno-transplanted breast cancer cell lines that overexpressing 
PRL-1 or PRL-3, respectively105. The study also provides evidence that a fraction of human 
breast cancer cells is able to take up antibodies, which is also significantly facilitated by 
serum-starving. The anti-tumor effect of PRL antibodies is further validated by the study 
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from the same group. A new generation of humanized PRL-3-zumab effectively inhibited 
tumor burden in orthotopic mouse model of PRL-3-positive human and mouse liver cancer 
cells and prolonged their survival. However, PRL-3-zumab did not affect cell growth of 
PRL-3-positivel live cancer cells in vitro. The difference between in vitro an in vivo was 
explained by that PRL-3-zumab treatment recruited B cells, NK cells and macrophages to 
the tumor micro-environment for its anti-tumor activity106. In total, these efforts support 
the concept that phosphatases are in fact druggable and suggest that PRL-3 is a feasible 















Figure 1. PRLs are Highly Homologous. The P-Loop and WPFDD Loop are critical to 
phosphatase activity. The prenylation motif targets PRLs to the plasma membrane. The 














Figure 2. Two-step Catalytic Mechanism of PTPs.  
PRLs share a canonical two-step catalytic mechanism with other PTPs. In step one, the 
thiolate anion of the Cysteine residue in the P-loop acts as a nucleophile, attacking the 
phosphate group on the substrate then forming a thiophosphoryl enzyme intermediate, 
and the second aspartate reside in the WPFDD loop acts as a general acid by donating a 
proton to the leaving group in the substrate. In step two, the same aspartate residue acts as 
a general base by activating a water molecule that can hydrolyze the enzyme-phosphate 
complex and then release the phosphate.











Decreased Stathmin protein expression but 
its phosphorylation by PRL-3 was not 
studied. 
Differential protein phosphorylation in 




Decreased CDH22 protein expression but 
direct de-phosphorylation of CDH22 by 
PRL-3 was not studied 
Yeast two-hybrid system/ co-IP/Co-
localization 
79
COS-7 Integrin α1 
Dephosphorylation of Integrin β1, direct de-
phosphorylation of Integrin α1 by PRL-3 
was not studied 
Yeast two-hybrid system/co-IP 76
HTC116 Elongation factor 2 
Dephosphorylation of Elongation factor 2, 
exact residue was not determined and 
physical association with PRL-3 was not 
determined 
Differential protein phosphorylation in 
PRL-3 overexpressing cells 
81
HTC116 Ezrin 
Dephosphorylation of Thr 567 of Ezrin but 
no evidence showing direct interaction with 
PRL-3 
Differential protein phosphorylation in 
PRL-3 overexpressing or knockdown 
cells/ in vitro de-phosphorylation assay 
81
/ PI (3,4,5) P3, PI (4,5) P2  
Dephosphorylation of PI (4,5) P2 and 
PI (3,4,5) P3 by PRL-3 in vitro but no in vivo 
evidence for PRL-3 lipid phosphatase 
activity 
In vitro phosphatase activity assay 82
COS-7 
HEK293 CNNM4 
Inhibits Mg2+ efflux mediated by 
CNNM1/2/3/4 Co-IP and in vitro binding assay 
107
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Table 3 Signaling Pathways Affected by PRL-3 
Models PRL-3 manipulation Altered signaling pathways Ref. 
SW480 (colorectal cancer cells) overexpression GTPase (RhoC) 108
A549 (lung cancer cells) Blocking with anti-PRL-3 antibody RhoA/C, ERK 
61
Hela (cervical cancer cells) Overexpression Arf1(ADP-ribosylation factor 1), integrin α5 
87
Hela (cervical cancer cells) 
DLD-1 (Colorectal cancer cells) Overexpression PI3K-AKT, GSK 3β, EMT 
88
MEFs (mouse embryonic fibroblasts) Overexpression/knockdown PI3K-AKT, p19Arf-p53-p21 89
HEK 293(Human embryonic kidney 
cells) 
SW480 and 620 (colorectal cancer cells) 
overexpression Src pathway, ER1/2K, STAT3, p130Cas. 91
Reh and MHH-CALL-4 
(preB-ALL cells) Knockdown Src, FAK (focal adhesion kinase) 
64
MOLM-14 (AML cells) overexpression STAT3/5, apoptotic pathway 79
SW480 (colorectal cancer cells) Overexpression /knockdown GSK 3β, β-catenin, Cadherin, EMT 79
HCT116 (colon cancer cells) Overexpression/knockdown P53 109
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Table 4 PRL inhibitors 
Inhibitor Potency and Selectivity Discovery Cellular efficacy Ref. 
Pentamidine 
Similar activity against PRL1/2/3: 
IC50 < 0.277μg/ml using peptide 
substrate; also shows activity against 
other phosphatases 
The clue comes from that 
Pentamidine has similar anti-
leishmania action as SSG, 
which has anti-cancer 
activity via inhibiting PTPs. 
Inhibits growth of five human 
cancer cell lines with PRL 
expression within the 
concentration ranges 0.3-
5μg/ml; inhibits growth of 
WM9 human melanoma 
tumors in nude mice and 
results in tumor necrosis. 
110
Thienopyridone 
PRL1: IC50 = 173 nM 
PRL2: IC50 = 277 nM 
PRL3: IC50 = 128 nM 
Shows selectivity over 11 other 
PTPs (DiFMUP). 
High-throughput screening 
of the Roche chemical 
library to search for 
molecules that inhibits PRL 
phosphatase activity using 
peptide substrate. 
Induces p130Cas cleavage and 
apoptosis in Hela and RKO 
cells; inhibits anchorage-
independent growth in RKO 
and HT-29 cells; inhibits 






PRL1: IC50 = 50 nM 
PRL2: IC50 = 53 nM 
PRL3: IC50 = 18 nM 
Minimal effect on PTP1B at 50 μM.
Identified during the process 
of SAR study of 
thienopyridone to increase its 
stability and reduce its 
potential toxicity. 
Inhibits the proliferation, 
spheroid viability, and 
migration of OvCa cells, and 
also impedes the in
vivo growth of drug-resistant 
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Inhibit human PRL3 activity with 
IC50 range 0.9 ~ 9.5 μM; compound 
5e is the most active one with IC50 
0.9 μM against PRL3; not tested on 
other PRLs and PTPs (DiFMUP).
Rhodanine skeleton was 
identified by high throughput 
screening of chemical library 
of Korean Chemical Bank 
and 14 derivatives were 
synthesized for SAR study.
Compound 5e reduces 





Inhibit human PRL3 activity: 
CG-707: IC50= 0.8 μM 
BR-1: IC50=1.1 μM 
Minimal effects on 9 other PTPs 
(DiFMUP). 
Suppress cancer cell migration: 
CG-707: IC50= 5 μM 
BR-1: IC50=7 μM 
Using cell-based assay to 
screen Rhodanine derivatives 
Inhibit the migration and 
invasion of cancers that express 
PRL3 without affecting 
proliferation; change the 
expression of EMT markers. 
113
Analog 3 
Inhibit human PRL3 activity PRL3: 
IC50 = 31 μM 
Shows acceptable selectivity against 
PTP1B, TCPTP and VHR and no 
selectivity against PRL1 and PRL2 
(DiFMUP). 
Ligand based virtual 
screening of Zinc database 
combined with SAR study 
and biochemical screening 
Specifically inhibits migration of 
cells that express PRLs in a 
dose-dependent manner and does 
not affects proliferation of HEK 
cells at 50 μM 
114
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Not phosphatase inhibitors, 
Trimerization disruptors 
30mg/kg cmpd-43 inhibits melanoma 
xenograft tumor growth; ~2μM cmpd-
43 suppress 50% MeWo cells survival 
(estimated from Fig 5D)
Sequential structure-based 
virtual screening of 
compounds of Asinex and 
ChemBridge subsets in the 
ZINC database.
Specifically inhibit cell 
proliferation and migration of 
PRL-1 overexpressing cells; 
suppress MeWo cells 
proliferation and migration, 




Inhibit human PRL3 activity PRL3: 
IC50 = 31 μM 
Shows acceptable selectivity against 
PTP1B, TCPTP and VHR and no 
selectivity against PRL1 and PRL2 
Extracted from spice 
turmeric, has been known to 
be able to induce apoptosis 
of cancer cells and suppress 
cell migration and 
angiogenesis. 
Inhibits mRNA expression of 
PRL3 and partial PRL2; 
specifically inhibits adhesion 
and migration of cancer cells 
with high PRL3 expression; 
inhibits growth and metastasis of 




Inhibited PRL3 activity: 
gfinkgetin: IC50 = 50 μM 
sciadopitysin: IC50 = 25.8 μM 
Not tested on other PTPs and PRLs 
Bioflavonoids identified in 
the MeOH extract of the 
young branches of Taxus 
cuspidate 
Reduce invasiveness of B16F10 







Inhibited PRL3 activity: 
Compound 1: IC50 = 5.2μg/ml 
Compound 2: IC50 = 1.3 μg/ml 
Not tested on other PRLs and PTPs. 
Extracted from the roots of 
Rubia akane. 
Compound 2 was shown to 
inhibit migration of DLD-1 cells 
but not proliferation. 
118
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High selectivity: PRL1 and PRL3 
mAb only prevents metastatic tumor 
formation of cells that express 
respective PRL. 
PRL3-zumab is more potent than 5-
FU, a first-line chemotherapeutic drug 
for gastric cancer.
Generated using hybridoma 
technology and their 
specificity was confirmed.
Efficiently and specifically 
block metastatic tumors 
formation of cells 
overexpressing PRL; also inhibit 
tumor formation of cancer cells 
expressing endogenous PRL; 
prevents recurrence of PRL3 





CHAPTER 3. PRL-3 DRIVES MIGRATION AND PROGRESSION OF T-ALL
IN VITRO AND IN VIVO 
3.1 Hypothesis and Specific Aims 
As discussed in Chapter 2, the oncogenic role of PRLs is well established, and they 
are considered attractive therapeutic targets in cancer. Before we move from bench to 
bedside, there are still critical questions need to be answered. For example, what are the 
physiological substrates of PRLs? What are the substrates in malignant conditions? Are the 
substrates dependent on cancer type? How are PRLs involved in regulating tumor 
progression?  How can we develop specific PRL-3 inhibitors to facilitate more in-depth 
study of PRL-3 or for therapeutic purposes? 
While the role of PRL-3 is well documented in solid tumors, its role in leukemia is 
less well defined and how PRL-3 contribute in T-ALL has not been reported. Our 
preliminary research suggests that PRL-3 could play an important role in T-ALL. Our lab 
previously performed an unbiased serial transplantation screen in the zebrafish Myc-
induced T-ALL model to identify genes and pathways that were highly expressed in T-
ALL clones as they evolved relapse potential, defined as acquisition of aggressive growth, 
increased self-renewal, and resistance to chemotherapy. RNAseq comparing these clones 
pre- and post-evolution showed that a subset of those with high relapse potential acquired 
high expression of PRL-3. Realtime RT-PCR analysis showed that PRL-3 was highly 
expressed in the zebrafish T-ALL samples that evolved high relapse potential but not in 
the samples with low relapse potential or in the normal whole blood/T cells, suggesting 
that PRL-3 could play a role in cell growth, maintenance of stemness or drug resistance. 
Given the oncogenic role of PRL-3 in multiple cancers, I hypothesized that PRL-3 plays a
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critical role in T-ALL progression by affecting cell survival, proliferation and/or 
migration. To test this hypothesis, three specific aims are developed: 1) To determine 
whether PRL-3 shows clinical relevance in T-ALL progression and relapse; 2) To 
determine whether PRL-3 affects T-ALL cells survival, proliferation or migration. 3) To 
identify PRL-3 substrates or interactomes. 
3.2 Materials and Methods 
3.2.1 Materials 
PE Anti-Human CD45 was obtained from Giolegend (Clone HI30, 304008). Mouse 
IgG-HRP and rabbit IgG-HRP were from Cell signaling (7106, Lot TC2625) and GeneTex 
(26741, Lot 9788061), respectively. Since the PRL antibody is notorious for its specificity 
and high homologous between PRLs leads to non-specific recognition, different PRL-3 
antibodies were obtained to test their specificity. Same amount of PRL-1, PRL-2 or PRL-
3 (0.3 ug) was loaded and different PRL antibody was used for western blot analysis. PRL-
3 antibody (Abcam50276) was shown to recognize PRL-3 but not PRL-1/2 while PRL pan 
antibody (R&D MAB32191) showed similar sensitivity to PRL-1 and PRL-2, but barely 
detects PRL-3 (Figure 3A). Therefore, all the Western blots about PRLs shown in the 
thesis are obtained using these two Abs.  
The PRL inhibitor, JMS-053, was kindly provided by Dr. John S. Lazo, Elizabeth 
Sharlowe, and Peter Wipf (University of Virginia, Charlottesville, VA, USA), and the Src 
inhibitor, SU6656, was purchased from Sigma-Aldrich (S9692, St. Louis, MO, USA). 
Lentiviral packaging plasmids psPAX2 (Addgene 12260, Watertown, MA, USA) 
and pMD2.G (Addgene 12259) were gifted from Didier Trono. pLenti PGK Puro DEST 
(w529-2) (hereafter referred to as PGK) (Addgene 19068) and pLenti PGK GFP Puro 
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(w509-5) (Addgene 19070) were gifts from Eric Campeau & Paul Kaufman. Non-targeting 
control pLKO shRNA lentivirus plasmid (MISSION, SHC002, Sigma-Aldrich) was kindly 
provided by Tianyan Gao and pLKO shRNAs targeting PRL-3 were purchased from 
Sigma-Aldrich; target sequences are listed in Table 5. 
pENTR:PRL-3 (human) and pENTR:prl-3 (zebrafish) Gateway Entry constructs 
were made by PCR amplifying PRL-3 and prl-3 from cDNA generated from human T-
ALL cells and 24h post-fertilization zebrafish embryos, respectively. The PCR products 
were subcloned into the pENTR-d-TOPO cloning vector (ThermoFisher K2400-20, 
Waltham, MA, USA). The Gateway compatible zebrafish rag2 vector and generation of 
the rag2:Myc and rag2:mCherry construct has been previously described120. The 
PGK:PRL-3 and rag2:prl-3 constructs were generated using the PGK destination vector 
and pENTR:PRL-3 or the rag2 destination vector and pENTR:prl-3 along with Gateway 
LR Clonase II enzyme mix, according to manufacturer’s protocol (ThermoFisher 
11791020). 
Frozen isolated PBMCs from de-identified T-ALL patients were kindly provided 
by Dr. Michelle Kelliher (University of Massachusetts Medical School, Worcester, MA, 
USA). PBMCs from healthy donors were purchased from Precision for Medicine 
(Bethesda, MD, USA). 
3.2.2 T-ALL Cell Lines and Cell Culture 
All the human T-ALL cell lines used in the study were authenticated by short 
tandem repeat (STR) DNA profiling and tested for mycoplasma contamination prior to 
experimentation. Cells were grown in RPMI1640 (ThermoFisher 11875119) 
supplemented with 10% heat-inactivated fetal bovine serum (Atlanta Biologicals, 
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S11150H, Lot M17161, Flowery Branch, GA, USA). Cells were cultured at 37°C in a 
humidified atmosphere with 5% CO2. 
3.2.3 Western Blot 
Western blot analysis was performed using a stain-free technology developed by 
BioRad, which allows us to use the total protein as the loading control121. For all figures 
shown, a band of total protein ~50kD size is used to represent the lane of total protein. 
An example was shown in Figure 3B. 
3.2.4 Microarray Data Analysis 
 The primary patient microarray datasets were accessed through the Gene 
Expression Ominbus (GEO) at NCBI (https://www.ncbi.nlm.nih.gov/geo), including 
GSE13159122,123, and 124,125  
3.2.5 Lentivirus Packaging and T-ALL Cells Infection 
For PRL-3 knock-down, lentivirus was produced in 293T cells using TransIT-
LT1 (Mirus Bio, Madison, WI, USA), according to the manufacturer’s instructions using 
scrambled or shPRL-3 plasmids. For T-ALL cell infection, 2.5mL virus with 10μg/mL 
polybrene (Thermo Fisher Scientific TR-1003-G) was added to 5x105 cells and 
centrifuged at 2250 rpm for 90 minutes. Virus was washed out with PBS after 24h, and 
cells were selected in culture media with 5μg/mL puromycin for 48h before experiments. 
To generate PRL-3-ovexpressing cell lines, 293T cells were transfected with 
PGK:GFP with or without PGK:PRL-3 as described above. T-ALL cells were infected 
with spin cycles and selected in medium with 5μg/mL puromycin (Jurkat) or 2μg/mL 
puromycin (HBPALL) for one week to produce stably expressing cell lines, then 
maintained in media with puromycin thereafter. 
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3.2.6 In Vitro Cell-based Assays 
The CellTiter-Glo Luminescent Cell Viability Assay (Promega, G7570, Madison, 
WI, USA) was used to measure cell survival according to the manufacturer's instructions. 
A Synergy LX BioTek (Winooski, VT, USA) multi-mode plate reader was used to read 
luminescent signal. 
Migration assays were performed as previously described69. Cells were starved in 
serum free medium overnight at the same density, then the cells were spun down and 
resuspended in serum free medium and plated in upper chamber of the transwell support. 
After 4 hours, the cells that migrated into the lower chamber were quantified by 
CellTiter-Glo Luminescent Cell Viability Assay. 
Cell cycle was analyzed by quantifying 5’-ethynyl-2’-deoxyuridine (EdU) uptake 
using ClickIT EdU Alexa Fluor 647 (Thermo Fisher Scientific, C10424) according to the 
manufacturer’s protocol. DAPI (0.1μg/ml) (ThermoFisher 62248) was also used to stain 
the DNA.  
Apoptosis was quantified by staining cells with Annexin V APC (ThermoFisher 
88-8007-74) according to the manufacturers protocol in the presence of DAPI 
(0.05μg/ml).  
3.2.7 Zebrafish T-ALL Models 
Use of zebrafish was approved by the University of Kentucky’s Institutional 
Animal Care and Use Committee (IACUC), protocol 2015-2225. Microinjections of 
15ng/μL rag2:Myc + 45ng/μL rag2:mCherry or 15ng/μL rag2:Myc + 15ng/μL rag2:prl-3 
+ 30ng/μL rag2:mCherry were used to generate zebrafish T-ALL in CG1 strain zebrafish 
as previously described, and number of animals used in each group were chosen based on 
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previous experiments90. Zebrafish were monitored for leukemia onset and progression 
starting at 21 days post-fertilization (dpf) and every 3 days onwards by analyzing percent 
of the body expressing mCherry-positive leukemia cells using a Nikon fluorescence-
equipped SMZ25 microscope. Circulating mCherry-positive T-ALL was noted by 
examining the vessels within the tail vasculature. Animals were monitored until 90 dpf or 
until they had to be sacrificed due to leukemia burden. Animals that died before the end 
of the monitoring period without leukemia progression outside the thymus were 
excluded.  Zebrafish leukemias were harvested and cytospin and May-Grunwald Giemsa 
staining were performed as previously described before imaging on a BioTek Lionheart 
FX microscope120,126. To assess gene expression, RNA was isolated from the cells using 
Zymo Research Quick-RNA kit (R1054, Irvine, CA, USA). Total RNA was reverse 
transcribed (BioRad iSCRIPT, 1708891) and real time PCR performed using iTaq 
Universal Sybr Green Supermix (Biorad, 1725120) with primer sequences available in 
Table 5. Data were normalized to ef1a expression and fold change was calculated using 
the 2-∆∆Cq method.   
3.2.8 Xenograft Models in Immune-compromised Mice 
Use of mice was approved by the University of Kentucky’s IACUC, protocol 
2017-2754. Eight-week old NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice were 
obtained from Jackson Laboratory (Bar Harbor, ME, USA). Eight mice per group were 
used for experiments based on pilot studies that utilized three mice per group. The mice 
were randomized by placing into groups such that the difference between average group 
weight is not greater than 10%. Jurkat cells were infected with Scrambled shRNA or 
PRL-3 shRNA as described above. Two days after virus infection, Jurkat cells were 
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selected using 5μg/ml puromycin for two days, stained with trypan blue, and viable cells 
were FACS isolated. 106 live cells in 100μL PBS were injected intravenously. Peripheral 
blood samples (100-150μL) were collected by submandibular bleeding at 4, 6, and 8 
weeks post-transplantation and stained with human CD45 antibody according to 
manufacturer’s protocol and analyzed by flow cytometry.  
3.2.9 Statistical Analysis 
Results are shown as mean ± standard deviation. Microarray expression analysis 
was supported by Biostatistics and Bioinformatics Shared Resource Facility at University 
of Kentucky.  Sample sizes of mice study were chosen based on pilot experiments 
utilizing 3 samples per group, and experiments were done unblinded. At least 3 biological 
replicates were performed in each experiment. Statistical analyses were performed using 
GraphPad Prism 7 (San Diego, CA, USA), combining data from all samples across all 
replicates. Two-tailed t-tests were performed to compare two groups with similar 
distribution, and Analysis of Variance (ANOVA) with Tukey’s multiple comparisons 
was used to compare more than two groups. Human microarray data were analyzed using 
two-sample t-test and Wilcoxon rank sum tests, and survival curves were analyzed using 
Log-rank tests. Difference in circulating zebrafish cells was analyzed using two sample t-
test between percents. All bar graphs shown are data pooled from ≥3 experiments. 
3.3  Results  
3.3.1 PRL-3 is Highly Expressed in T-ALL 
Given the important role of PRL-3 in solid tumor progression and the fact that it 
is under-explored in leukemia, it is important to identify the function of PRL-3 in T-ALL. 
First PRL-3 expression was examined in bone marrow samples from T-ALL patient and 
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healthy donors using gene expression datasets deposited in the Oncomine database 
(GSE13159). These data revealed that PRL-3 mRNA expression is significantly higher 
(p=6.8e-10) in T-ALL samples (n=174) compared to that from healthy donors (n=72, 
Figure 4A). In GSE14615, we saw no significant difference in PRL-3 expression between 
patients who achieved complete remission (n=29) versus those that relapsed (n=11) or 
suffered induction failure (n=7, Figure 4B). However, the sample size was relatively 
small in this study, and further investigation is warranted to determine whether PRL-3 
expression is a predictor for T-ALL treatment failure. Western blot showed 3 out of 8 T-
ALL patient peripheral blood mononuclear cell (PBMC) samples, which contain high 
percentage of circulating leukemic cells, expressed very high PRL-3, while it is detected 
at low levels, if at all, in PBMCs from 5 healthy donors (Figure 4C).  
Additionally, PRL-3 protein was expressed at varying levels across 14 T-ALL cell 
lines (Figure 5A). Interestingly, PRL-3 expression in the same cell line fluctuated 
notably across independent assays (Figure 5B), although we did not find the expression 
level to be related to cell density or serum deprivation. 
 Analysis of other PRL family members showed that PRL-1 expression was 
significantly lower in primary T-ALL patient samples compared to healthy bone marrow, 
while PRL-2 expression is significantly higher (Figure 6A and 6B). Consistent with 
gene expression datasets, PRL-1 was not detected across T-ALL cell lines, while PRL-2 
is expressed in most T-ALL cell lines examined (Figure 7A and 7B). 
3.3.2 PRL-3 Promotes Cell migration, but Not Growth, in T-ALL Cells 
PRL-3 knock-down or inhibition has been shown to impair cell growth in solid 
tumor cell lines57,112. In order to define the role of PRL-3 in T-ALL, shRNAs were used 
 
 42 
to knock down PRL-3 expression in Jurkat cells, a T-ALL line with high endogenous 
PRL-3 expression. Western blot analysis of samples collected four days after lentiviral 
infection of shRNA constructs showed that PRL-3 was successfully knocked-down by 
shRNA constructs #2 and #3 compared to scrambled (SCR) control shRNA (Figure 8A). 
Expression of PRL-2 did not increase to compensate for PRL-3 loss and again, PRL-1 
was not detected (Figure 8A). Interestingly, despite puromycin selection of the shRNA 
construct, PRL-3 expression levels recovered over time (Figure 8B), suggesting that cells 
with higher PRL-3 expression may outcompete those with stronger knock-down.  
Cell growth of PRL-3 knockdown Jurkat cells was compared to controls cell, 
which were transfected by scrambled shRNA (SCR). Cells subjected to 5μg/ml 
puromycin selection for 2 days were plated and cell growth were measured by CellTiter 
Glow assay up to 3 days. Unexpectedly, PRL-3 knockdown did not negatively impact 
cell growth (Figure 9A).  
As previous studies have shown that PRL-3 is also involved in solid tumor cell 
migration127,128, we next examined whether PRL-3 knockdown affects cell migration 
since migration of leukemic cells might be related to their capacity of central nervous 
system (CNS) infiltration129. PRL-3 knock-down Jurkat cells were serum starved, then 
their ability to migrate through a trans-well towards a serum stimulus over a 4h period 
was quantified. As shown in Figure 9B, silencing PRL-3 expression significantly 
reduced cell migration by ~50% (p<0.02). Similarly, when we overexpressed PRL-3 in 
Jurkat and HBP-ALL cells (Figure 10A), we found no significant difference in cell 
growth (Figure 10C), but significantly increased migratory capability compared to 
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control (p≤0.009, Figure 10B). Together, these data suggest that PRL-3 plays an 
important role in regulating cell migration, but not cell growth, in T-ALL cells in vitro 
3.3.3 PRL-3 Knock-down Impairs Human T-ALL Engraftment in a Xenograft 
Mouse Model 
In order to determine whether silencing PRL-3 expression in human T-ALL 
affects its oncogenic ability in vivo, xenotransplantation of T-ALL was performed using 
PRL-3 knock-down Jurkat cells. As shown in Figure 11A, Jurkat cells expressing a 
scrambled shRNA or a shRNA targeting PRL-3 were injected intravenously into 
immune-compromised mice. At 4, 6, and 8 weeks after transplantation, blood samples 
were collected and stained with anti-human CD45. Flow cytometry showed no human 
CD45-positive cells in the circulation of mice injected with PRL-3 knock-down Jurkat 
cells, while mice injected with Jurkat expressing scrambled shRNA cells showed 
increasing numbers of CD45 positive cells in the blood each week (Figure 11B and 
11C). Three mice harboring scrambled shRNA expressing T-ALL had to be euthanized 
before the 8-week time point due to mobility issues likely resulting from T-ALL 
infiltration into the spinal column, while mice with PRL-3 knock-down remained healthy 
throughout the study. Together, these data show that PRL-3 significantly affects 
engraftment and circulation of human T-ALL cells xenografted into mice. 
3.3.4  PRL-3 Enhances T-ALL Onset in a Zebrafish Model 
The elevated expression of PRL-3 in T-ALL patient samples and its role in 
promoting migration in T-ALL cell lines suggests it may play an oncogenic role in T-
ALL. A zebrafish Myc-induced T-ALL model, which was generated to express mouse c-
myc under control of the zebrafish Rag2 promoter, was used to assess the role of PRL-3 
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in T-ALL onset and progression. It has been shown that T-ALL arose in the zebrafish 
thymus, then spread locally into gill arches and retro-orbital soft tissue, and eventually 
spread to skeletal muscle and abdominal organs120,126  
In our study, one-cell stage zebrafish embryos were injected with plasmids 
containing rag2:Myc with rag2:mCherry, and with or without rag2:prl-3. Zebrafish prl-3 
has 88% homology to human PRL-3 with conservation of the critical domains130. 
Leukemia developed in the fish that incorporated mouse Myc in their chromosome.  As 
the leukemia cells also express fluorescent protein mCherry, T-ALL onset and 
progression in these fish were monitored by using fluorescent microscope.  Growth of T-
ALL growth was quantified by the percent mCherry-positive cells within the body of the 
animal; >70% mCherry-positive was considered leukemic.  It was observed that T-ALL 
develops in zebrafish from the thymus and expands into local tissues before entering the 
circulation. Zebrafish T-ALL that expressed prl-3 consistently expanded from the thymus 
earlier than T-ALLs expressing Myc alone (Figure 12A), and there was significant 
difference in time to full leukemia onset between the groups (Figure 12B).  
Because the T-ALL cells were fluorescently labeled, the time at which leukemia 
cells begin to circulate was determined by visualizing cells within the vasculature in the 
tail fin (Figure 13A, Supplemental Videos 1 and 2131). While more than half of animals 
with T-ALL in the Myc-expressing group never developed circulating disease by >100 d ( 
Supplemental Video 1131), more than 80% of the Myc+prl-3 expressing T-ALLs were 




The lymphoblasts were morphologically similar between the groups (Figure 
14A), and there was no significant difference in Myc expression between Myc and 
Myc+prl-3 T-ALL samples (Figure 14B). Gene expression analyses indicated that both 
the rag2:Myc and rag2:Myc+rag2:prl-3 leukemias expressed the lymphocyte specific 
genes rag1 and rag2 and the T-cell genes lck and tcrB-C2, but not B-cell related genes 
Pax5, igD or igM, indicating all leukemias generated were of T-cell origin. We verified 
that the rag2: Myc+rag2: prl-3 leukemias expressed >10-fold higher levels of Prl-3 than 
the Myc control group (Figure 14C). Interestingly, endogenous prl-3 expression was also 
significantly higher in the rag2: myc T-ALLs than normal blood, suggesting that PRL-3 
may be an important collaborating oncogene in T-ALL development.   
Taken together, these data suggest that PRL-3 can play an important role in T-
ALL onset and progression in vivo, likely by enhancing migration into local tissues and 
contributing to the ability of the cells to enter circulation. 
3.4 Discussion  
Treatment outcomes of ALL have been improved dramatically over the last 
several decades with survival rates exceeding 80%. However, there is a disparity in the 
number of available immunotherapies and molecular targeted therapies available in T-
ALL compared to other leukemia subtypes, correlating with a worse patient prognosis in 
patients who fail traditional chemotherapy regimens. Additionally, CNS infiltration by T-
ALL, both CNS and bone marrow relapse remain critical clinical challenges, with 
survival rates of relapsed disease as low as 40%132. The identification and 
characterization of important drivers of T-ALL progression is needed for the design of 
novel, targeted therapeutics.  
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We found PRL-3 was highly expressed in T-ALL patient samples and cell lines, 
consistent with studies reporting PRL-3 up-regulation in solid tumors133 and B-ALL64. 
Importantly, we used two different animal models to demonstrate an oncogenic role of 
PRL-3 in T-ALL, which, to our knowledge, is the first in vivo study demonstrating an 
oncogenic role for PRL-3 in T-ALL. The overexpression of PRL-3 in the transgenic 
zebrafish T-ALL model showed that PRL-3 expression enhanced the spread of T-ALL 
cells out of the thymus and promoted their rapid entry into circulation, while human T-
ALL cells with silenced PRL-3 lost their ability to engraft and grow in NSG mice. While 
we hypothesize the lack of T-ALL engraftment associated with PRL-3 knock-down may 
be attributed to a decreased ability of the leukemia cells to migrate and home to the bone 
marrow or thymus niche after xenograft, this needs to be confirmed experimentally. 
Given PRL-3 is established as enhancing viability and preventing apoptosis in other 
cancers70, PRL-3 might be playing additionally roles in vivo that contribute to fitness of 
the T-ALL cells.   
Overall, our study suggests that PRL-3 functions in T-ALL to promote cell 
migration, both in vitro and in vivo. While cell migration is critical to solid tumor 
progression, and PRL-3 has well-established roles there, in leukemia, the contribution of 
migration towards disease progression is less defined. In T-ALL, CCR7, a known 
regulator of T lymphocyte migration, has been demonstrated to be necessary and 
sufficient to drive infiltration of T-ALL cells into the CNS in a mouse model129. Another 
regulator of cell migration, CXCR3, has also been reported to be involved in ALL 
progression, in which CXCR3 inhibition significantly reduced leukemic infiltration into 
bone marrow, spleen and CNS134. Although whether PRL-3 can modulate known 
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lymphocyte migratory signals, such as CCR7 or CXCR3, to promote T-ALL migration 
and possibly CNS relapse remains to be determined; there is clearly a precedent for 








Figure 3. Antibody Specificity and Total Protein as Loading Control for Western 
Blot. 
(A) Antibody against PRL-3 (Abcam, 50276) detects purified PRL-3 protein specifically 
but not PRL-1 and 2. Human PRL pan specific antibody (MAB3219) detects both PRL-1 
and PRL-2 at similar sensitivity but barely detects PRL-3. Recombinant human PRL-1 
(8490-PT), PRL-2 (6694-PT) and PRL-3 (8455-PT) proteins were from R&D systems 
and 0.3 μg of each protein was loaded in 4-20% protein TGX stain-free gel (BioRad, cat 
#4568093).(B) All the Western blot analysis were performed using a stain-free 
technology developed by BioRad, which uses total protein loaded for each sample as the 
loading control. Protein was separated on TGX-stain free pre-casted 4-20% SDS gel, 
which allows the image of total protein, as shown in left, by exposing the gel under the 
UV activation in the ChemiDoc Imaging System. Representative bands from the total 
protein gel instead of the whole image of the gel were shown in the Western blots results 













Figure 4. PRL-3 is Highly Expressed in Human T-ALL Patient Samples.  
(A) Microarray expression analysis of GSE13159 comparing PRL-3 expression in bone 
marrow samples from T-ALL patients to that from healthy donors **p=6.8e-10. (B) 
Analysis of GSE14615 comparing PRL-3 expression between samples from T-ALL 
patients achieving remission and the patients with induction failure. NS=not significant. 
(C) Representative western blot analysis of primary patient T-ALL samples compared to 
PBMCs from healthy donors. Representative bands from total protein loaded were used 












Figure 5. PRL-3 is Highly Expressed in T-ALL Cell Lines 
 (A) Representative western blot analysis of human T-ALL cell lines, showing PRL-3 
expression. Representative bands from total protein loaded were used for loading control. 
(B) Quantification of 3 independent western blots across cell lines, showing PRL-3 














 Figure 6. High expression of PRL-2 in Human T-ALL Patient Samples 
 (A) Microarray analysis of GSE14615 showing PRL-1 is down-regulated in bone 
marrow samples from T-ALL patient compared to that from healthy donors. *p<0.001. 
(B) Microarray analysis of GSE14615 showing PRL-2 is up-regulated in bone marrow 











Figure 7. PRL-2 Protein is Highly Expressed in T-ALL Cell Lines 
 (A) Representative western blot analysis of PRL-1 and PRL-2 in human T-ALL cell 
lines, showing PRL-2 expression in a subset of T-ALL cell lines. Representative bands 
from total protein loaded were used for loading control. (B) Quantification of 3 
independent western blots cross human T-ALL cell lines, showing that PRL-2 expression 












Figure 8. PRL-3 Knock-down in T-ALL Cells 
 (A) Representative western analysis figure showing PRL-3 expression was inhibited in 
Jurkat T-ALL cells 4d post-infection with lentivirus carrying shRNA. PRL-2 expression 
does not change upon PRL-3 knockdown, indicating PRL-2 does not compensate for 
PRL-3 loss. Numbers represent relative expression of PRL-3 or PRL-2 protein, 
normalized to total protein and compared to scrambled (SCR) control. (B) Jurkat cells, 
which showed PRL-3 complete knock-down at day 5 post lentiviral infection (Figure 
8A) were cultured for 6 and 7 days and total protein was extracted for western blot 
analysis, showing that PRL-3 expression returns over time. The numbers in the blot are 




















Figure 9. PRL-3 Knockdown Inhibits Cell Migration. 
 (A) Cells infected with SCR or PRL-3 knock-down shRNA were cultured in media 4 
days post-infection with 5μg/ml puromycin for 72 additional hours. Cell growth was 
determined by Cell Titer-Glo assay and normalized to the readout of day 0 and showed 
no difference between groups. Data shown are the average of 3 independent experiments, 
done in triplicate, NS=not significant. (B) Knock-down of PRL-3 in Jurkat cell line 
reduced migration towards a serum stimulus more than 50%. Migration was normalized 







Figure 10. PRL-3 Over-expression Promotes Cell Migration in T-ALL 
 (A) Western blot analysis showed expression of PRL-3 in Jurkat and HBP-ALL cell 
lines after infection with lentivirus harboring PGK: GFP or PGK:PRL-3. (B) High PRL-3 
expression increased cell migration in T-ALL cells. Migration was normalized to control 
cells expressing GFP only, **p<0.001, ***p<0.0001. For all bar graphs, data are the 
average of at least three independent experiments, done in triplicate. (C) T-ALL cells 
expressing PGK: PRL-3 (PRL-3 OE) or PGK:GFP (GFP) were cultured in medium with 
puromycin for 72 hours. Cell growth was determined by Cell Titer-glow assay and 
normalized to the readout of day 0, and showed no difference between PRL-3 
overexpressing cells and control cells at all time points. Data shown are the average of 3 































Figure 11 PRL-3 Knock-down Impairs T-ALL Engraftment in Mice.  
(A) Schematic diagram of the xenotransplantation assay. (B) Representative flow 
cytometry analysis of submandibular blood sample after human CD45 staining.  (C) 
Quantification of human CD45 staining of mice blood at week 4,6 and 8 after 
transplantation. Each dot represents one mouse, the horizontal line represents the mean 
value, and the standard deviation is shown, *p<0.01 and **p<0.001 compared to shRNA 
















Figure 12. PRL-3 Enhances Leukemia Onset in a Zebrafish T-ALL Model.  
(A) Representative images of transient transgenic zebrafish expressing rag2: 
Myc+rag2:mCherry (n=11) or rag2:Myc+rag2:mCherry+rag2:prl-3 (n=6) at 34 days 
post-fertilization (dpf). (B) Kaplan-Meier analysis of time (days) percent survival (>70% 
of animal is mCherry-positive). Data shown in this figure were collected and analyzed by 
















Figure 13. PRL-3 Enhances Leukemia Circulation in a Zebrafish T-ALL Model.   
(A) Representative rag2: Myc+rag2:mCherry+rag2:prl-3 animal, showing circulating 
mCherry+ leukemia cells within the tail fin. (B) Kaplan-Meier analysis of time (days) for 
each T-ALL to be visualized in circulation, * p=0.049. Data shown in this figure were 











Figure 14. Prl-3 is Highly Expressed in Leukemia Zebrafish T-ALL Model.  
 (A) Representative images of May-Gunwald Giemsa staining of blood samples from fish 
from each leukemia type. Scale bar=100μm. (B) Realtime RT-PCR analysis of Myc 
expression between rag2 :Myc+rag2:mCherry (n=8) and rag2: Myc + rag2: mCherry + 
rag2: prl-3 (n=5), showing that Myc expression is not differentially expressed between 
the groups.  Each point represents one fish sample. NS=not significant. (C) Realtime RT-
PCR analysis of lymphocyte, T-cell, and B-cell specific genes, demonstrating that 
leukemia is of T-cell origin.  Bars are the average expression of three samples per group. 











Table 5 shRNA Sequence Used for PRL-3 Knock-down 
ShRNA Target sequence 
PRL-3 shRNA#1 CTACAAACACATGCGCTTCCT 
PRL-3 shRNA#2 TCTCGGCACCTTAAATTATTA 




 Table 6 Realtime RT-PCR Primer Sequences 
Gene Forward Primer Reverse Primer Purpose 
z-ptp4a3 GGTGTCACGACAGTGGTCAG TCAATCAAGGCCACAGCCAC PRL-3 expression 
z-rag1 AGCAATGATGCAAGGCAGAG TGTGCAGGGGCTGGAATATC Lymphocytes 
z-rag2 AGCTCTCAGATTTCGGAGTACAC ACAAGGCTGCCACAATTCAC Lymphocytes 
z-lck AGAAGATCTCGATGGTTTGTCTGT CGCAGTTCCCCATGTTTACG T-cell 
z-tcr β-c2 ATTCACCTGCACTGTCCGAT AGCTTCAATCCCTTCGGCTT T-cell 
z-pax5 CTGATTACAAACGCCAAAAC CTAAATTATGCGCAGAAACG B-cell 
z-igD GAGAGCAGCAAAAGGATGGC TGCAAGTTTGGTCTTGTTCTGC B-cell 
z-IgM-VH1 CATGACAATGGATATTGTGTCC ACATGAAGGTTGCTGATCCAC B-cell 
m-Myc AGCGACTCTGAAGAAGAGCAA GCACCTCTTGAGGACCAGTG / 





CHAPTER 4. PRL-3 REGULATES SRC PATHWAY TO PROMOTE CELL 
MIGRATION 
4.1 Introduction  
In vitro and in vivo data suggest that PRL-3 functions in T-ALL progression 
likely by modulating leukemia cell migration. Since PRL-3 is a phosphatase and multiple 
oncogenic signaling pathways are shown to be regulated in cancer cell models as 
discussed in Chapter 2, it is possible that PRL-3 affects critical signaling pathways 
involved in cell migration via de-phosphorylation. To test this hypothesis, we next 
examined the gene signatures related to PRL-3 high expression in T-ALL patients and 
signaling pathways that are affected by PRL-3 knockdown or ectopic expression in T-
ALL cells at protein level. 
4.2 Materials and Methods 
4.2.1 Materials 
Antibodies used in this study, including their manufacturer, catalog number, lot 
number, blocking buffer used, and dilution factor are listed in Table 7. 
4.2.2 Co-immunoprecipitation 
Cells (~50 million) were lysed in Pierce IP lysis buffer (Thermo 87788) 
supplemented with 1% Protease Inhibitor Cocktail (Sigma P8465). Total protein was 
incubated with 80 μL Anti-Flag M2 magnetic beads (Sigma m8823) on shaker overnight. 
After removing supernatant and washing the beads with PBS gently, the magnetic  
beads were boiled with 50 μL SDS containing buffer to elute the immunoprecipitants 




4.2.3 Gene Set Enrichment Analysis  
Gene Set Enrichment Analysis was done using GSEA 4.0.0. PRL-3 expression 
levels, corresponding to Affymetrix probes 209695_at and 206574_at were used for 
phenotypic labeling. Enrichment was calculated using MSigDB collection C6, oncogenic 
gene sets. Gene set enrichment was considered significant if it had a nominal p-value 
<0.05. 
4.2.4 RPPA Assay and Data Processing 
Reverse Phase Protein Array (RPPA) and data analysis were performed by the 
RPPA Core Facility at MD Anderson Cancer Center (Houston, TX, USA) as previously 
described135. Briefly, total protein extracted from cells was printed on nitrocellulose-
coated slides using an Aushon Biosystems 2470 Arrayer. Slides were probed with 
antibodies previously validated by the core, and signals reflecting protein abundance 
were visualized by a secondary streptavidin conjugated HRP and DAB colorimetric 
reaction. The slides were scanned, analyzed, and quantified using Array-Pro Analyzer 
software (MediaCybernetics) to generate spot intensity. SuperCurve GUI was used to 
estimate relative protein levels (in log2 scale). A fitted curve ("supercurve") was created 
with signal intensities on the Y-axis and relative log2 amounts of each protein on the X-
axis using a non-parametric, monotone increasing B-spline model. Raw spot intensity 
data were adjusted to correct spatial bias before model fitting using “control spots” 
arrayed across the slide. A QC metric was generated for each slide to determine slide 
quality and only slides with 0.8 on a 0-1 scale were used. Protein measurements were 
corrected for loading using median centering across antibodies. Samples with low protein 




4.2.5 In Vitro Cell-based Assays 
The CellTiter-Glo Luminescent Cell Viability Assay (Promega, G7570, Madison, 
WI, USA) was used to measure cell survival according to the manufacturer's instructions. 
A Synergy LX BioTek (Winooski, VT, USA) multi-mode plate reader was used to read 
luminescent signal. 
Migration assays was performed as previously described49. In experiments using 
JMS-053 or SU6656, cells were pre-treated with JMS-053, SU6656 or DMSO control for 
2h before plating into the upper chamber. The cells that migrated into the lower chamber 
were quantified by CellTiter-Glo Luminescent Cell Viability Assay. 
4.2.6 Statistical Analysis 
Results are shown as mean ± standard deviation. At least 3 biological replicates 
were performed in each experiment. Statistical analyses were performed using GraphPad 
Prism 7 (San Diego, CA, USA), combining data from all samples across all replicates. 
Two-tailed t-tests were performed to compare two groups with similar distribution, and 
Analysis of Variance (ANOVA) with Tukey’s multiple comparisons was used to 
compare more than two groups. Human microarray data were analyzed using two-sample 
t-test and Wilcoxon rank sum tests, and survival curves were analyzed using Log-rank 
tests. All bar graphs shown are data pooled from ≥3 experiments. 
4.3 Results  
4.3.1 PRL-3 Regulates Src Activity in T-ALL Cells 
To identify a mechanism by which PRL-3 might contribute to cell motility, we 
first examined gene signatures associated with PRL-3 expression in T-ALL patient 
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samples. T-ALL samples with high levels of PRL-3 (upper quartile) and low levels of 
PRL-3 (lower quartile) were selected from GSE13159 (Figure 4A) for Gene Set 
Enrichment Analysis (GSEA), which identified that genes linked with SRC kinase 
signaling (Figure 15A ), embryonic stem cell signature (Figure 15B ), and VEGF 
(Figure 15C ) pathways were significantly enriched in PRL-3 high T-ALL.   
In order to examine the protein phosphorylation mediated by PRL-3, a high 
throughput antibody-based functional proteomic analysis, Reverse-Phase Protein Array 
(RPPA), was used to examine the differential protein expression in PRL-3 knockdown or 
overexpressing cells. In this experiment, total proteins were extracted from Jurkat GFP 
versus Jurkat PRL-3 OE cells or Jurkat cells transfected with scramble versus PRL-3 
shRNA, denature by SDS, printed on nitrocellulose-coated slides, which are then probed 
by 442 different proteins, including 86 phospho-proteins. The result showed 23 proteins 
are greater than 20% differential expressed between Jurkat cells transfected with 
scramble or PRL-3 shRNA (Figure 16A and Supplemental Table 270). RPPA on PRL-3 
overexpressing Jurkat cells compared to control cells identified 21 proteins with more 
than 30% differential expression (Figure 16B and Supplemental Table 370). Expression 
of Histone-H3, Chk2, and Src_pY527 were affected in both PRL-3 knock-down and 
overexpressing cells.  
Both GSEA and RPPA data suggest that the SRC pathway is associated with 
PRL-3 expression at both the mRNA and protein level. Src is a non-receptor kinase that 
is activated in a large fraction of cancers, where it plays a prominent role in cell 
migration and metastasis90. Src activity is regulated by phosphorylation, where Tyrosine 
527 and tyrosine 416 are two critical phosphorylation sites that regulate Src activity 
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(Figure 17). Tyrosine phosphatases dephosphorylate the pTyr-527 to stabilize the 
open/active conformation of Src. Further phosphorylation of tyrosine 416 locks the 
catalytic pocket of Src into the fully active conformation. The fully activated Src then 
phosphorylate its substrate proteins. The pTyr-527 of Src is also regulated by CSK (C-
terminal Src Kinase), which add phosphorylation modification to Tyr 527, leading to 
inhibition of Src activity. In other words, activation of Src pathway occurs by 
dephosphorylation of the 527 residue and by phosphorylation of the 416 residue.  
In order to validate the changes in Src pathway expression seen in RPPA studies, 
Western blot was performed using PRL-3 knock-down or overexpressing T-ALL cell 
lines. Cells with PRL-3 overexpression had decreased phosphorylation of Src_p527 at all 
time points compared to control (Figure 18A-B), while total Src protein expression was 
not affected. Conversely, PRL-3 knock-down in Jurkat cells increased total Src protein 
expression and phosphorylation of Src_Y527 (Figure 19A-B). Interestingly, CSK 
expression was inversely correlated with PRL-3 expression (Figure 18A and 19A), 
consistent with previous reports that found PRL-3 down-regulates CSK expression in 
human embryonic kidney cells and colon cancer cell91. 
Together, these data show that genetic manipulation of PRL-3 in T-ALL cells can 
modulate Src activity by affecting phosphorylation of Src itself as well as affecting 
expression of kinases known to phosphorylate Src. 
4.3.2 Src is not a PRL-3 Direct Substrate 
The effect of PRL-3 on phosphorylation of Src_Y527 may be through a direct 
action of PRL-3 phosphatase activity or through an indirect mechanism such as 
regulation of CSK or other proteins. In order to answer this question, a PRL-3 mutant, 
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PRL-3 (C104S) was used in the following study. The PRL-3 (C104S) mutant is 
phosphatase deficient but still retain the binding affinity to its substrates. Over-expressing 
PRL-3 (C104S) mutant in Jurkat cells partially rescued the reduction of Src_Y527 
phosphorylation compared to PRL-3 wild-type expression (Figure 20A-B), suggesting 
that PRL-3 phosphatase activity likely plays a role in Src regulation. Importantly, PRL-3 
(C104S) has been previously shown to retain a low level of phosphatase activity48; the 
artificially high level of exogenous PRL-3(C104S) expression in the Jurkat cells may 
therefore compensate for reduced phosphatase activity, leading to incomplete rescue of 
the phosphorylation of Src_Y527.   
Next, Jurkat cells expressing 3XFlag PRL-3 or PRL-3 (C104S) was used for co-
immunoprecipitation assay to determine whether PRL-3 is physically associated with Src.  
Interestingly, Src did not co-immunoprecipitate with Flag-tagged PRL-3 or PRL-3 
(C104S), despite being found at high levels in Jurkat cell lysate (Figure 20C). Our results 
indicate that Src is not a direct substrate of PRL-3 in T-ALL and PRL-3 modulates 
Src_Y527 phosphorylation by either inhibiting CSK expression, or via an unknown 
protein intermediate (Figure 20A and 20D). 
4.3.3  PRL Inhibitor, JMS-053, Inhibits T-ALL Cell Migration via Src Pathway. 
T-ALL migration plays a critical role in T-ALL progression and our data show 
PRL-3 can directly affect the migratory phenotype of T-ALL cells both in vitro and in 
vivo. As small molecule inhibition of PRL-3 can block solid tumor progression70, it 
would have translational potential if PRL-3 inhibition by small molecules also shows 
similar effects. JMS-053, the most potent and specific PRL inhibitor, was used to 
examine how PRL-3 inhibition affects T-ALL. This non-competitive PRL inhibitor, JMS-
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053102, significantly reduced the viability of T-ALL cells in a dose dependent manner 
(Figure 21A), with lesser to no effects in cell lines that did not routinely express high 
levels of PRL-3. PRL-3 inhibition increased apoptosis in T-ALL cells after 24h, although 
this trend was not significant across multiple experiments (Figure 21B). PRL-3 inhibition 
did not show any effect on cell cycle, measured by EdU uptake (Figure 21C). Short-term 
(<2hr) JMS-053 treatment significantly (p<0.001) impaired the migration capability of all 
PRL-3 expressing T-ALL cell lines tested, reducing cell migration through a transwell 
towards a serum stimulus by 30-80% (Figure 22A). JMS-053 treatment increased the 
phosphorylation Src_Y527 (Figure 22B), again indicating that PRL-3 might promote cell 
migration by activation of Src. 
Finally, in order to determine whether the effect of JMS on cells migration is via 
Src pathways, a Src inhibitor, Su6656, was used to treat PRL-3 over-expressing cells in 
combination with JMS-053 and evaluated whether the inhibitors synergized to affect cell 
migration capability. While both JMS-053 and Su6656 significantly decreased cell 
migration compared to control, no significant additive effect was detected when both 
inhibitors were used (Figure 22C), supporting the hypothesis that PRL-3 modulates Src 
signaling to promote cell migration.  Taken together, our data showed that small 
molecule inhibition of PRL-3 blocks T-ALL growth and migration in vitro, likely due to 
Src inhibition, and suggest that PRL-3 might be a useful target to control T-ALL 
progression. 
4.4 Discussion 
Here we explored a mechanism how PRL-3 enhance T-ALL migration and 
progression. We have demonstrated that PRL-3 modulates the Src signaling pathway in 
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T-ALL cell lines. Src activation has been reported in many types of human cancer, with a 
prominent role in regulating motility, migration, and metastasis90,136,137. PRL-3 has been 
previously reported to play a role in Src pathway activation in solid tumors and benign 
human cell lines91,138.  Our study expanded the role of PRL-3 in Src signaling pathway 
modulation to include T-ALL, suggesting that PRL-3 might be a central regulator of the 
Src signaling network across multiple cancer types. However, we could not conclude 
whether PRL-3 acts directly on Src protein to dephosphorylate the Y527 residue, or 
whether it modulates expression CSK protein, causing an indirect decrease in Src_Y537 
phosphorylation. Additionally, our RPPA analyses determined that the expression of 
other proteins were affected by PRL-3, including Histone-H3, Chk2, JNK, Hes1, Rictor, 
Axl, and Hif1-alpha, all of which play known roles in tumor progression, and may 
represent novel mechanisms by which PRL-3 promotes T-ALL.  
In summary, the oncogenic role of PRL-3 was expanded to T-ALL using both in 
vitro and in vivo assays in our study. PRL-3 was found to promote T-ALL 
development/onset in zebrafish models and play a role in engraftment in mouse xenograft 
models. Importantly, we also found that chemical inhibition of PRL-3 can inhibit cell 
growth and migration, suggesting that PRL-3 is a feasible therapeutic target in T-ALL. 
Cell-culture based assays revealed that PRL-3 modulates Src signaling in T-ALL to 
enhance migratory capability, with no significant effect on cell growth. Given that several 
genes involved in T cell migration promote CNS and bone marrow relapse, further 
studies on the role of PRL-3 in CNS infiltration and relapse of T-ALL are necessary. Our 
findings present a strong rationale for developing targeted therapies targeting PRL-3 
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signaling. There is increasing interest in developing PRL-3 inhibitors for use in solid 















Figure 15. GSEA Analysis Reveals Pathways Enriched in PRL-3 High patient 
samples.  
Gene Set Enrichment Analysis of T-ALL patient samples (GSE13159) comparing bone 
marrow with high PRL-3 expression (upper quartile) vs low PRL-3 expression (bottom 
quartile) identified that (A) SRC pathway, (B) Embryonic stem cell gene signatures, and 












Figure 16. Reverse Phase Protein Array Analysis (RPPA) 
 of (A) PRL-3 knock-down or (B) over-expression of PRL-3 3 in Jurkat cells showed 
differential protein expression when compared to controls. Red bars show any protein 
that was up or down regulated 20%, and protein names shown in red are common in both 































Figure 17. Schematic of Src Pathway  
Src is one member of Src family tyrosine kinases, which is composed of SH3 (Src 
homology 3) and SH2 (Src homology 2) domain, the kinase domain, and the C-terminus 
regulatory tail. The phosphorylation of tyrosine residue (Tyr-527 and Tyr-416) in the C-












Figure 18. Src Pathway is Activated in PRL-3 Overexpressing Jurkat Cells.(A) 
Western blot validation of Src pathway in PRL-3 overexpressing Jurkat cells. Cells were 
serum starved overnight and added to serum containing complete media for the indicated 
time points. Src_pY527 and CSK protein were consistently decreased in PRL-3 over-
expressing Jurkat cells but not GFP expressing control cells. Numbers shown represent 
relative protein expression. (B) Quantification of Src_pY527 western blots representing 
at least n=3 independent experiments in PRL-3 OE Jurkat cells. Box plots show the mean 












Figure 19. Src Pathway is Inhibited in PRL-3 Knockdown Cells  
(A) Representative western blot analysis of Src_pY527, total Src, and CSK in Jurkat cells 
with PRL-3 knock-down, and (B) quantification of at least 3 independent experiments in 












Figure 20. Src is Not a Direct Substrate of PRL-3  
(A) Representative western blot validation of Src pathway in 3×Flag PRL-3 Wt and 
3×Flag PRL-3 C104S mutant Jurkat cells, showing that PRL-3 C104S overexpression 
partially rescue reduction of Src_Y527 phosphorylation (B) Quantification of n=4 
independent experiments analyzing SRC_pY527, *p=0.003. (C) Co-immunoprecipitation 
assay of Jurkat overexpressing PRL-3 substrate trapping mutants, 3×Flag PRL-3 C104S 
or 3×Flag PRL-3 C104D, did not pulldown Src. (D) Schematic of PRL-3 and modulation 













Figure 21. PRL-3 Inhibition does not Affect T-ALL Cell Apoptosis and Proliferation   
(A) JMS-053 inhibits cell viability, evaluated by quantifying ATP production via Cell-
Titer Glo, *p≤0.001 or NS=not significant, compared to DMSO. There is no significant 
difference in apoptosis (B) or cell cycle (C) in JMS-053 treated cells, compared to 







Figure 22. PRL-3 Enhances Migration of Jurkat Cells via Src Pathway 
(A) JMS-053 treatment (10μM) for 2 h suppressed cell migration of T-ALL cells, 
**p<0.001 compared to DMSO. For all, bars are the average of three experiments, each 
done in triplicate, ± standard deviation. (B) JMS-053 (10 µM) treatment increased Src 
phosphorylation at tyrosine 527. Blots are representative of at least 3 independent 
experiments. The numbers in the blot are relative expression normalized to total protein 
loaded. (C) Cell migration capability of PRL-3 over-expressing cells was compared 
between groups treated with DMSO, Src inhibitor Su6656 (2.5μM), JMS-053 (10μM) or 























Anti-Src Cell Signaling (Clone 32G6, 2123, Lot 5) Rabbit 1:1000 
Anti-Src_pY416 Cell Signaling (Clone D49G4, 6943, Lot 4) Rabbit 1:1000 
Anti-Src_pY527 Cell Signaling (2105, Lot 9) Rabbit 1:1000 
Anti-CSK Cell Signaling (Clone C74C1,4980, Lot 2) Rabbit 1:1000 
Mouse IgG-HRP Cell Signaling (7106, Lot TC2625) Goat 1:5000 
Rabbit IgG-HRP GeneTex (26741, Lot 9788061) Goat 1:5000 





CHAPTER 5. IDENTIFICATION OF PRL-3 INTERACTOMES IN T-ALL 
5.1 Introduction 
Critical questions remain to be answered in the PRL-3 research field. For 
example, PRL-3’s substrates and its exact molecular mechanisms involved in cancer 
progression and relapse are largely unknown70. The weak and transient interactions 
between PRL-3 and its substrates due to its extremely wide and shallow catalytic pocket47 
makes the isolation of PRL-3 complexed with its substrate really difficult. This challenge 
is reflected ty the lack of reports on PRL-3 substrates.  Only keratin 875and integrin β177 
have shown evidence as PRL-3 direct substrates in the literature.  The phosphorylation of 
keratin 8 and integrin β1 was regulated by PRL-3 overexpression or knockdown. More 
importantly, the direct interaction between PRL-3 and keratin 8 or integrin β1 was 
demonstrated by Co-IP and/or co-localization assays. A few other PRL-3 interacting 
proteins, not necessarily direct targets, have been reported (Table 2). It seems that PRL-3 
substrates are cancer type dependent and no PRL-3 substrates in leukemia have been 
reported. As discussed in Chapter 4, Src pathway is regulated by PRL-3 via de-
phosphorylation at tyrosine 527 in T-ALL. However, Src is not a direct substrate of PRL-
3. The identification of PRL-3 substrates in T-ALL would be helpful to understand the 
mechanism of how PRL-3 contribute to tumor progression and migration.  
In order to study PRL-3 substrates in T-ALL, a BioID-based proximity labeling 
approach (Figure 23A) was used to characterize PRL-3 interacting proteins to start with. 
The advantages of this approach over other traditional methods to study interactomes is 
in that it can be used to identify the proteins that weakly or transiently interact with the 
protein of interest and is also effective to study insoluble, inaccessible, or low-abundant 
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interacting protein139. Briefly, BioID2, a biotin ligase, is fused to PRL-3 protein and 
overexpressed in cells, where BioID2 biotinylates interacting/adjacent proteins (Figure 
23B). As biotinylation is a rare protein modification, biotin modified proteins in this 
experiment are candidates for interacting proteins with PRL-3. Then a biotin-affinity 
capture method can be used to pull down the biotin-labeled proteins and mass 
spectrometry will be used to identify these proteins. 
5.2 Materials and Methods 
5.2.1 Antibodies, DNA Plasmids and Other Reagents 
Antibodies used in this study, including their manufacturer, catalog number, lot 
number, blocking buffer used, and dilution factor are listed in Table 8. 
Lentiviral packaging plasmids psPAX2 (Addgene 12260, Watertown, MA, USA) 
and pMD2.G (Addgene 12259) were from Didier Trono, pLenti PGK Puro DEST (w529-
2, hereafter referred to as PGK) (Addgene 19068) and pLenti PGK GFP puro (w509-5, 
hereafter referred to PGK:GFP) (Addgene 19070) were from Eric Campeau & Paul 
Kaufman. MCS-BioID2-HA (Addgene 74224) was from Kyle Roux. QuikChange 
Lightning Site-Directed Mutagenesis Kit was from Agilent (210518). 
pENTR: BioID2-HA-PRL-3 Gateway Entry construct was made from Gibson 
assembly, where BioID2-HA was PCR amplified from MCS-BioID2-HA with a 
homologous overhang to NcoI linearized pENTR: PRL-3 and pENTR: PRL-3 was 
digested with NcoI. The PGK: BioID2-HA-PRL-3 was generated using the PGK 
destination vector and pENTR: BioID2-HA-PRL-3. PGK: BioID2-HA was generated by 
introducing an out-of-frame insertion in the PRL-3 domain in PGK: BioID2-HA-PRL-3 to 
disrupt PRL-3 translation using a QuikChange Lightning Site‑ Directed Mutagenesis kit.  
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PGK: 3×Flag PRL-3 Wt was generated by LR cloning using pENTR: 3×Flag 
PRL-3 and PGK destination vector, according to manufacturer’s protocol (ThermoFisher 
11791020). PGK:3×Flag PRL-3 C104S was generated using QuikChange Lightning 
Site‑ Directed Mutagenesis kit. 
The buffers and reagents used in Biotinylated protein pulldown are listed in Table 
9.  
5.2.2 T-ALL Cell Lines and Cell Culture 
The human T-ALL cell lines used in the study were authenticated by short tandem 
repeat (STR) DNA profiling and tested for mycoplasma contamination prior to 
experimentation. Cells were grown in RPMI1640 (ThermoFisher 11875119) 
supplemented with 10% heat-inactivated fetal bovine serum (Atlanta Biologicals, 
S11150H, Lot M17161, Flowery Branch, GA, USA). Cells were at 37°C in a humidified 
atmosphere with 5% CO2.  
5.2.3 Lentivirus Packaging and T-ALL Cells Infection 
Lentivirus was produced in 293T cells using TransIT-LT1 (Mirus Bio MR2300, 
Madison, WI, USA), according to the manufacturer’s instructions using PGK:BioID2-HA 
or  PGK: BioID2-HA-PRL-3.  To generate cell lines that overexpress baits, 2.5mL virus 
with 10μg/mL polybrene (Thermo Fisher Scientific TR-1003-G) was added to 5x105 cells 
and centrifuged at 2250 rpm for 90 minutes. Virus was washed out with PBS after 24h, 
and cells were selected in culture media with puromycin (5μg/mL for Jurkat cells and 
2μg/mL for HBP-ALL cells) produce stable cell lines, then maintained in media with 
puromycin thereafter.  
 
 82 
5.2.4 Biotinylated Protein Immunoprecipitation  
For small scale biotinylated protein immunoprecipitation, cells were incubated 
with 50 μM biotin for 16 h prior to harvesting. About 30 million cells were collected and 
washed in cold PBS twice, then cells were lysed in 1ml Pierce RIPA buffer (Thermo 
Scientific 89900) supplemented with protease inhibitor at 4°C with shaking for 30 
minutes. The supernatant was collected and incubated with 200 μL of Dynabeads 
overnight. Beads were collected using a magnetic stand and washed three times with cold 
PBS. Then the beads-protein complex was boiled in 50 μL SDS containing buffer to elute 
the biotinylated protein from the beads. Total protein and eluted biotinylated protein were 
used for western blot analysis.  
Large scale biotinylated protein pulldown was performed by the Proteomics 
Shared Resources at Sanford Burnham Prebys as previously described140. Briefly, prior to 
harvesting, cells were incubated with 50 μM biotin for 16 h. 100 million cells were 
collected and washed in cold PBS twice, then cells were lysed in 2.4 ml of cell lysis 
buffer with two times of sonication,  each for 1 min at 30% duty cycle and an output level 
of 4 (Sonifer-250; Branson).  2.4 ml of 50 mM Tris (pH 7.4) as added to the cell lysate 
and spun at 16,500 × g for 10 min. The supernatant was collected to a 15-ml conical tube 
and incubated with 300 μL of Dynabeads overnight. Beads were collected using a 
magnetic stand and washed twice with wash buffer 1, once with wash buffer 2, once with 
wash buffer 3 and once in buffer 4. Finally, beads-biotinylated protein complex was used 




5.2.5 Mass Spectrometry and Data Analysis 
Mass spectrometry analysis and analysis was performed by the Proteomics Shared 
Resources facility at Sanford Burnham Prebys as previously described139. Briefly, beads-
biotinylated protein complexes captured in 4.2.4 were resuspended in 50 μL of 8 M 
urea/50 mM ammonium bicarbonate and 2 μL of 0.5 M Tris (2-carboxyethyl) phosphine 
was added to the suspension, then incubated for 60 min at 30°C to reduce the protein. 
After cooling down the reaction, 4 μL of 0.5 M iodoacetamide was added for alkylation 
at room temperature in the dark for 30 min. 350 μL of 50 mM ammonium bicarbonate 
was added to the reaction to dilute the 8 M urea to 1 M prior to trypsin digestion. 
Overnight digestion was performed at 30° with shaking at 700 rpm by adding 5 μg of 
MS-grade trypsin (Promega, Madison, WI) to the protein-bead complexes. Digested 
peptides were isolated from the beads by centrifugation and magnetic separation, then 
transferred to a new tube. The beads were washed in 50 μL of 50 mM ammonium 
bicarbonate to collect peptide residues, which were pooled with the previous peptide 
solution. Formic acid was added to the peptide solution (final concentration 2%), which 
was then desalted by using Microtrap (77720; Thermo Scientific, Waltham, MA). 
Finally, 10% of total peptides in duplicate runs were performed using a high-resolution, 
high-accuracy LC-MS/MS system , which includes an EASY-nLC 1000 HPLC, Acclaim 
PepMap peptide trap, 25 cm × 2 μm Easy-Spray C18 column, Easy Spray Source, and Q 
Exactive Plus mass spectrometer (all from Thermo Fisher Scientific).  
The LC-MS/MS raw data of three technical replicates were combined and 
submitted to Sorcerer Enterprise, version 3.5 (Sage-N Research, Milpitas, CA) with 
SEQUEST algorithm as the search program for peptide/protein identification. SEQUEST 
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was set up to search the target-decoy EBI.IPI.HUAMAN (version 3.73) protein database 
containing protein sequences, using trypsin for enzyme with an allowance of up to two 
missed cleavages, Semi Tryptic search, fixed modification of 57 Da for cysteine to 
account for carboxyamidomethylation, and precursor mass tolerance of 50 ppm. 
Differential search includes 16 Da for methionine oxidation and 226 on lysine for 
biotinylation. The search results were viewed, sorted, filtered, and statistically analyzed 
by using comprehensive proteomics data analysis software Peptide/Protein prophet, 
version 4.02 (ISB). The minimum transproteomic pipeline (TPP) probability score for 
proteins was set to 0.9 to assure very low error (much less than a false discovery rate of 
2%) with reasonably good sensitivity. The differential spectral count analysis was done 
by QTools, an open-source in-house–developed tool for automated differential 
peptide/protein spectral count analysis. Proteins with fewer than three spectral counts or 
common MS background proteins, including keratins, histones, and ribosomal proteins, 
were removed due to the lack of confidence. Any candidate identified by BioID2-PRL-3 
was excluded if the relative percentage of total spectral counts was threefold less than in 
the BioID2-only.  
5.2.6 Western Blot 
Western blot analysis was performed using a stain-free technology developed by 
BioRad, which allows for the use of total protein as the loading control121. For all figures 
shown, a band of total protein ~50kD is size is used to represent the lane of total protein. 





Cells (~50 million) were lysed in Pierce IP lysis buffer (Thermo 87788) 
supplemented with 1% Protease Inhibitor Cocktail (Sigma P8465). Total protein was 
incubated with 80 μL Anti-Flag M2 magnetic beads (Sigma m8823) on shaker overnight. 
After removing supernatant and washing the beads with PBS gently, the magnetic beads 
were boiled with 50 μL SDS containing buffer to elute the immunoprecipitants from the 
beads. Total cell lysates and immunoprecipitants were used for western blot analysis.  
5.2.8 Statistical Analysis 
Fisher’s Exact test was performed in PANTHER Overrepresentation Test.  
5.3 Results 
5.3.1 BioID2 Expression Led to Biotinylation of Proteins in T-ALL 
In order to use BioID2-based proximal labeling to study PRL-3 interacting 
proteins in T-ALL, we overexpressed fusion proteins BioID2-PRL-3 or BioID2 in two T-
ALL cell lines, HSB2 and Jurkat. Overexpression of BioID2 in HSB2 or Jurkat cells 
(hereafter referred as HB/JB) and BioID2-PRL-3 in HSB2 or Jurkat cells (hereafeter 
referred as HBP/JBP) was validated by western blot analysis (Figure 24A). As shown in 
Figure 24B, incubation of HB/JB or HBP/JBP cells in biotin rich medium led to global 
biotinylation of proteins.  
5.3.2 Identification of PRL-3 Proximal Proteins 
A large scale Strep-avidin pulldown followed by mass spectrometry was 
performed to identify PRL-3 interacting proteins. Duplicates of 10 × 107 BioID2-PRL-3 
cells or BioID2 cells (control), processed in parallel, were analyzed for the experiment. 
The cells were incubated in Biotin-rich medium (50 μM) for 16hrs prior to cell lysis for 
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total protein. Biotinylated proteins were pulled down by streptavidin magnetic beads, 
rigorously washed and analyzed by mass spectrometry. Large amounts of diverse proteins 
(~3000) were identified by mass spectrometry.  
It is challenging to determine which protein represent bona fide PRL-3 interactors 
versus those that are background contaminants or proximal proteins but not really 
interacting with PRL-3. As background contaminants are mostly bait-independent, the 
proteomics community collected proteins presents in the negative controls from large 
amounts of the affinity purification- mass spectrometry (AP-MS) studies to generate an 
open data base, Contaminant Repository for Affinity Purification (the CRAPome)119. The 
CRAPome was used to score the proteins identified in the BioID2-MS experiment and 
only the proteins with CRAPome <0.5, which represents the protein present in <50% AP-
MS studies and less likely to be contaminants, were used for the next step analysis.  
As proteins that interact with PRL-3 should have higher level of biotinylation in 
BioID2-PRL-3 cells compared with that in BioID2 only cells, the fold-change of 
biotinylated proteins in BioID2-PRL-3 cells versus BioID2 cells was plotted (Figure 
24A), which showed four distinct clusters: Cluster A represents the proteins that showed 
Log2 Foldchange >3.3 of biotinylation  in JBP cells but not in HBP cells versus their 
respective controls. Cluster B represents the proteins that showed Log2 Foldchange >3.3 
fold-change in both HBP and JBP cells. Most of the proteins in Cluster B showed the 
CRAPome score equal to 0 ( green dots in Figure 24A), suggesting these are unique 
proteins captured by this BioID2-MS approach. Cluster C represents the proteins that 
showed Log2 Flodchange <3.3 of biotinylation in both HBP and JBP cells. Cluster D 
represents the proteins that showed Log2 Flodchange >3.3 of biotinylation in HBP cells 
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but not in JBP cells. The two previously reported PRL-3 interacting proteins, CNNM3 
(Log 2 Foldchange = 9.75 in HBP and Log 2 Foldchange = 9.44 in JBP) and CNNM4 
(Log 2 Foldchange = 8.57 in HBP and Log 2 Foldchange = 9.21 in JBP), were found in 
cluster b. PRL-3 protein itself also showed high level of biotinylation (Log2 Foldchange 
= 11.16 in HBP and Log2 Foldchange = 11.53 in JBP).  
In order to identify PRL-3 direct interacting proteins in T-ALL, we first analyzed 
proteins in cluste B, 288 common biotinylated proteins in both HBP and JBP, using 
PANTHER Overrepresentation Test ( Figure 25B). The PANTHER Overepresentation 
Test revealed the top 8 pathways that those common biotinylated proteins are enriched in, 
including α-adrenergic receptor signaling pathway, T cell activation, 5HT2 type receptor 
mediated signaling pathway, oxytocin receptor mediated signaling pathway, B cell 
activtaiton, thyrotropin-releasing hormone receptor signaling pathway, PDGF signaling 
pathway and endothelin singliang pathway.  
5.3.3 Validation of Biotinylated Proteins  
Identification of protein interactomes using AP-MS normally produces high rates 
of false positives. Although CRAPome scoring was used previously in the study to 
exclude most background contaminants, which are generally introduced at the 
purification stage, the false positives could also be generated by tandem MS step, such as 
misidentified by database searching algorithms. Therefore, validation of the interacting 
proteins identified by MS is important. Based on the PANTHER analysis and biological 
significance of the proteins in T-ALL, we decided to examine the biotinylation status of 
top hits LCK (lymphocyte-specific protein tyrosine kinase), CD3ε (cluster of 
differentiation 3 T cell co-receptor ε subunit), Notch1, Rictor (Rapamycin-insensitive 
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companion of mammalian target of rapamycin), LAT (Linker for activation of T cells) 
and CXCR4 (C-X-C chemokine receptor type 4) in JBP and JB cells using streptavidin 
pulldown followed by western blot analysis. JB and JBP cells were cultured in biotin rich 
medium (50 μM) for 16 hours prior to harvesting and then total protein was extracted for 
streptavidin pulldown assay. After rigorous washing, the biotinylated proteins bound to 
the streptavidin magnetic beads were denatured, released from the beads when subject to 
boiling in buffer containing beta mercaptoethanol and probed using western blot analysis 
(Figure 26A). We found that LAT and CXCR4 were not biotinylated in JB or JBP cells, 
biotinylated Notch 1 is found at a higher level in JB cells compared to JBP cells, 
suggesting non-specific biotinylation. These hits were excluded from further analysis. 
Biotinylation of LCK, CD3ε and Rictor was significantly higher in JBP cells compared to 
JB cells, suggesting that LCK, CD3ε and Rictor are potential PRL-3 interacting proteins.  
5.3.4 Identification of Direct Interacting Protein of PRL-3  
As BioID2-PRL-3 biotinylates all the proximal proteins of PRL-3, the 
biotinylated LCK, CD3ε, and Rictor identified by streptavidin pulldown and MS are not 
necessarily proteins that directly interact with PRL-3, but instead may be in close 
proximity. In order to examine whether LCK, CD3ε, Notch I and Rictor directly interact 
with PRL-3 or not, we generated Jurkat cells that express 3×Flag PRL-3 Wt, 3×Flag 
PRL-3 C104S, which is a catalytic inactive and substrate trapping PRL-3 mutant48, and 
Jurkat GFP control cells for co-immunoprecipitation assay. As shown in Figure 26B, 
anti-Flag magnetic beads pulled down Flag-PRL-3 Wt or C104S together with LCK and 
CD3ε but not Rictor  
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In order to know whether the formation of PRL-3: LCK: CD3ε complex is 
dependent on PRL-3 phosphatase activity, we next performed the same co-IP assay with 
or without the presence of a phosphatase inhibitor, vanadate. The total protein lysate of 
Jurkat GFP or 3×Flag PRL-3 Wt or 3×Flag PRL-3 C104S were split into two different 
tubes, one with and one without vanadate (2 mM) treatment followed by incubation at 4° 
C with shaking for 1h. Then, anti-Flag magnetic beads were added to the cell lysate with 
or without vanadate to pull down 3×Flag PRL-3 or C104S together with their binding 
proteins. As shown in Figure 26C, the addition of vanadate to the cell lysate did not 
disrupt the PRL-3: LCK: CD3ε complex, suggesting the formation of the complex is not 
dependent on PRL-3’s phosphatase activity.  
5.4 Discussion 
PRL-3 substrates are largely unknown, and although PRl-3 was found to modulate 
Src signaling to promote migration in T-ALL, the direct substrate of PRL-3 has not been 
found in T-ALL. Here we used a BioID2-based proximal labeling approach followed by 
MS to identify a pool of PRL-3 interacting proteins. Subsequent western blot validation 
of biotinylated proteins identified by MS demonstrated that a high percentage of PRL-3 
proximal proteins captured by BioID2 proximal labeling are actually biotinylated, 
suggesting that BioID2 approach to study PRL-3 interacting proteins is feasible and 
provides hints for substrate exploration and discovery. The co-IP assay revealed a 3-
protein complex, PRL-3: LCK: CD3ε, suggesting that PRL-3 is physically associated 
with LCK and/or CD3ε, both of which are critical components of T cell receptor (TCR) 
signaling. In the canonical TCR signaling model, a critical step is that LCK/Fyn (Src 
family tyrosine-protein kinase) phosphorylates immunoreceptor tyrosine-based activation 
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motif (ITAM) on CD3, which then serve as docking site for another tyrosine kinase ZAP-
70. ZAP-70 is also activated by LCK via phosphorylation, then continues to 
phosphorylate LAT, an adaptor protein, which further recruits downstream signaling 
molecules, including Slp76, phospholipase C1, Grb2, and GADS, resulting in T-cell 
activation141,142. LCK hyperactivation was associated with glucocorticoid resistance in 
pediatric T-ALL patients and chemical inhibition or genetic knockdown of LCK was able 
to reverse glucocorticoid resistance in T-ALL cell lines and patient-derived xenografts 
(PDX) cells. One of the mechanisms that LCK mediates GC resistance is via 
calcineurin/NFAT pathway that leads to the upregulation of IL-4143. LCK hyperactivation 
was also found in early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL), 
which is critical for T-cell leukemogenesis144.  
Our co-IP study found that PRL-3 and LCK were in the same protein complex. It 
is possible that PRL-3 can modulate LCK activity via de-phosphorylation. Another 
possibility is that PRL-3 acts as a scaffold protein that brings LCK and CD3 together and 
modulates LCK/TCR signaling pathway. We need to further determine that whether CD3 







Figure 23. Schematic of BioID2 Proximal Labeling to Identify PRL-3 Interactomes. 
(A)Principal of BioID2 proximal labeling. BioID2, a biotin ligase, is fused to your 
interest of protein to generate the bait protein. When the bait protein is expressed in the 
cells, the proximal proteins around the bait protein will be biotinylated, captured by 
affinity purification, and their identify can be determined by MS. (B) Expression of 
BioID2-PRL-3 fusion protein in T-ALL cells, Jurkat and HSB2,  leads to the selective 
biotinylation of proteins proximate to PRL-3. Biotinylated proteins are purified by Strep-













Figure 24. Expression of BioID2-PRL-3 Led to Biotinylation of Proteins.  
(A) Expression of BioID2-PRL-3 or BioID2 was detected HSB2 and Jurkat cell lines that 
were transfected with lentivirus followed by puromycin selection. (B) Incubation of 
HSB2 and Jurkat cells that overexpress BioID2 or BioID2-PRL-3 in biotin rich medium 
(50μM) for 16 hours led to biotinylation of proteins. HB, HSB2-BioID2; HBP, HSB2-






Figure 25. Identification of Biotinylated Proteins in BioID2-PRL-3 or BioID2.  
(A)The biotinylated proteins were pulled down by streptavidin magnetic beads and 
identified by mass spectrometry. Proteins with a CRAPome score >0.5131, which are 
likely to be contaminants, were excluded. CNNM481 and CNNM391 were previously 
reported as direct interacting protein of PRL-3. The color represents different CRAPome 
score (0-0.49) and size of the dot represents unique peptides identified by MS. (B) 288 
common biotinylated protein that were present in both HBP and JBP and Log2 
Foldchange >3.3 folds with unique peptides>3 were selected for PANTHER 
Overrepresentation Test (PANTHER 14.1), which showed top 8 pathways enriched in 









Figure 26. Identification of PRL-3 Interacting Proteins.  
(A) Representative figure showed biotinylated LCK or CD3ε or Rictor were enriched by 
streptavidin pulldown in Jurkat-BioID2-PRL-3 (JBP) cells compared with Jurkat-BioID2 
(JB) cells, which were cultured in biotin-rich medium prior to pulldown. (B) Co-IP by 
anti-Flag using Jurkat 3×Flag PRL-3 Wt or Jurkat 3×Flag PRL-3 C104S or Jurkat GFP 
(control) cells showed a PRL-3: LCK: CD3 complex. The figure is a representative figure 
of n=3 (C) The presence of vanadate (2mM) in the total protein of Jurkat 3×Flag PRL-3 
Wt or Jurkat 3×Flag PRL-3 C104S cells for Co-IP did not disrupt the formation of a 




Table 8 List of Antibodies, Their source and Working dilutions 




Streptavidin-HRP Cell Signaling (3999S, Lot 7) / 1:1000 
Anti-BioID2 BioFronTech (BID2-CP-100,  
Lot 03290116) 
Chicken 1:10000 
Anti-LCK Cell Signaling (6943, Lot 4) Rabbit 1:1000 
Anti-LCK_pY505 Cell Signaling (2751, Lot 7) Rabbit 1:1000 
Anti-LCK_pY394 Genetex (GTX133876, Lot 42935 Rabbit 1:1000 
Anti-CD3 ε  Cell Signaling (2105, Lot 9) Rabbit 1:1000 
Anti-Rictor Cell Signaling (21147, Lot 7) Rabbit 1:1000 
Anti-Notch1 Cell Signaling (3608, Lot 8) Rabbit 1:1000 
Anti- LAT Cell Signaling (45533, Lot 1) Rabbit 1:1000 
Anti-CXCR4 Abcam (ab124824, Lot GR3231217-6) Rabbit 1:1000 
Anti-Flag M2 Sigma (F1804, Lot SLBK1346V) Mouse  1:1000 
Anti-Flag M2 Cell Signaling (14793, Lot 5) Rabbit 1:1000 
Mouse IgG-HRP Cell Signaling (7106, Lot TC2625) Goat 1:5000 
Rabbit IgG-HRP Genetex (26741, Lot 9788061) Goat 1:5000 
Chicken IgY-HRP Abcam (ab97135, Lot GR320991-9) Goat 1:10000 
Blocking buffer  5% milk in 1% TBST / / 




Table 9 Reagents and Buffers for BioID2 Pulldown Assay 
Name Source or formula 
Halt Phosphatase Inhibitor Cocktail Life Technologies 
Dynabeads™ MyOne™ 
Streptavidin C1 R&D (MAB32191, Lot XJS01) 
Cell lysis buffer 
50 mM Tris, pH 7.4, 500 mM NaCl, 0.4% SDS, 
1 mM dithiothreitol, and 1× protease inhibitor 
Wash buffer 1 2% (wt./vol) SDS 
Wash buffer 2 
0.1% deoxycholate, 1% Triton X-100, 500 mM 
NaCl, 1 mM EDTA, and 50 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid, 
pH 7.5 
Wash buffer 3 
250 mM LiCl, 0.5% NP-40, 0.5% deoxycholate, 
1 mM EDTA, and 10 mM Tris, pH 8 





CHAPTER 6. FINAL CONCLUSIONS AND FUTURE DIRECTION 
6.1 Final Conclusion 
The overall goal of this dissertation is to understand the role of the protein 
tyrosine phosphatase PRL-3 in T-ALL progression and explore the potential of PRL-3 as 
therapeutic target for T-ALL. The results presented in this dissertation showed that PRL-
3 is highly expressed at both the mRNA level and protein level in T-ALL patients. PRL-3 
shows minimal effect on T-ALL survival and proliferation but contributes to cell 
migration capability, which enhances T-ALL progression and circulation in both 
transgenic zebrafish and xenotransplantation mice models. We also identified that the Src 
signaling pathways is affected by PRL-3 in T-ALL. Although Src is not a direct substrate 
of PRL-3, Src_pY527 is indirectly modulated by PRL-3, which is critically involved in 
cell migration. In addition, we applied the newly developed BioID2-based proximal 
labeling approach to study PRL-3 interactomes and identified a potential PRL-3 
substrate, LCK, which also belongs to the Src family and is essential for T-cell 
development. More importantly, our study showed that PRL-3 inhibition using a small 
molecule inhibitor, JMS-053, did inhibit T-ALL viability and migration, demonstrating 
that PRL-3 is targetable in T-ALL. According to our knowledge, this is the first study to 
demonstrate the oncogenic role of PRL-3 in T-ALL.  
6.2 Future Directions 
This is the first study to show that PRL-3 facilitates T-ALL progression and 
circulation. PRL-3 is under-explored in T-ALL and there is very limited information of 
possible genetic alterations of PRL-3 in T-ALL or other types of leukemia although there 
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is evidence that PRL-3 is highly expressed in T-ALL patient samples compared to that in 
normal control. Therefore, we need to profile PRL-3 status in T-ALL patient in order to 
understand its prevalence and importance in T-ALL. One of the mechanisms behind the 
oncogenic role of PRL-3 is via the Src signaling pathway, probably via direct interaction 
with LCK and/or CD3, the exact pathway by which PRL-3 affects the Src pathway is still 
unknown. In addition, we cannot exclude other pathways affected by PRL-3, which 
might also contribute T-ALL initiation and PRL-3. In order to answer these questions, 
further investigation is necessary to explore the direct substrate(s) of PRL-3. The BioID2 
approach identified a large pool of PRL-3 interacting proteins, which can serve as starting 
point for validation of PRL-3 direct substrates. However, it is not practical to validate all 
the interactomes of PRL-3 using the conventional co-IP or western blot analysis due to 
the large number of PRL-3 interactomes. In order to resolve this issue, high throughput 
approaches, such as unbiased proteomics, can be used to identify differential 
phosphorylation of LCK or CD3 upon PRL-3 inhibition or overexpression in cell line. 
The proteins that can be both biotinylated by BioID2-PRL-3 and their phosphorylation 
level is affected by PRL-3 are promising candidates for PRL-3 substrates. 
In our study, we found a PRL-3: LCK:CD3 complex using a BioID2 approach 
combined with co-IP assay. Whether PRL-3 directly interacts with LCK or CD3 remains 
unknown. Structural approaches, such as crystallography and cross-linking MS are 







1. Terwilliger, T. & Abdul-Hay, M. Acute lymphoblastic leukemia: a comprehensive 
review and 2017 update. Blood Cancer J. (2017) doi:10.1038/bcj.2017.53. 
2. Hunger, S. P. & Mullighan, C. G. Acute lymphoblastic leukemia in children. New 
England Journal of Medicine (2015) doi:10.1056/NEJMra1400972. 
3. Mody, R. et al. Twenty-five-year follow-up among survivors of childhood acute 
lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study. 
Blood (2008) doi:10.1182/blood-2007-10-117150. 
4. Luskin, M. R. & DeAngelo, D. J. T‑ cell acute lymphoblastic leukemia: Current 
approach and future directions. Adv. CELL GENE Ther. (2019) 
doi:10.1002/acg2.70. 
5. Nguyen, K. et al. Factors influencing survival after relapse from acute 
lymphoblastic leukemia: A Children’s Oncology Group study. Leukemia (2008) 
doi:10.1038/leu.2008.251. 
6. Schrappe, M. et al. Outcomes after induction failure in childhood acute 
lymphoblastic leukemia. N. Engl. J. Med. (2012) doi:10.1056/NEJMoa1110169. 
7. Vora, A. Childhood Acute Lymphoblastic Leukemia. (2017). 
8. Hunger, S. P. et al. Improved survival for children and adolescents with acute 
lymphoblastic leukemia between 1990 and 2005: A report from the children’s 
oncology group. J. Clin. Oncol. (2012) doi:10.1200/JCO.2011.37.8018. 
9. McMahon, C. M. & Luger, S. M. Relapsed T Cell ALL: Current Approaches and 
New Directions. Current Hematologic Malignancy Reports (2019) 
doi:10.1007/s11899-019-00501-3. 
10. Fielding, A. K. et al. UKALLXII/ECOG2993: Addition of imatinib to a standard 
treatment regimen enhances long-term outcomes in Philadelphia positive acute 
lymphoblastic leukemia. Blood (2014) doi:10.1182/blood-2013-09-529008. 
11. Uy, N., Nadeau, M., Stahl, M. & Zeidan, A. M. Inotuzumab ozogamicin in the 
treatment of relapsed/refractory acute B cell lymphoblastic leukemia. Journal of 
Blood Medicine (2018) doi:10.2147/JBM.S136575. 
12. Dal Bo, M. et al. New insights into the pharmacological, immunological, and 
CAR-T-cell approaches in the treatment of hepatocellular carcinoma. Drug Resist. 
Updat. 51, 100702 (2020). 
13. Tsaouli, G., Ferretti, E., Bellavia, D., Vacca, A. & Felli, M. P. Notch/CXCR4 
partnership in acute lymphoblastic leukemia progression. Journal of Immunology 
Research (2019) doi:10.1155/2019/5601396. 
14. Clappier, E. et al. NOTCH1 and FBXW7 mutations have a favorable impact on 
early response to treatment, but not on outcome, in children with T-cell acute 
lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951. 
Leukemia (2010) doi:10.1038/leu.2010.205. 
15. Aste-Amézaga, M. et al. Characterization of notch1 antibodies that inhibit 
signaling of both normal and mutated notch1 receptors. PLoS One (2010) 
doi:10.1371/journal.pone.0009094. 
16. Agnusdei, V. et al. Therapeutic antibody targeting of Notch1 in T-acute 
lymphoblastic leukemia xenografts. Leukemia (2014) doi:10.1038/leu.2013.183. 
 
 100 
17. Palomero, T. et al. CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) 
rearrangement, aberrant NOTCH1 activation and high sensitivity to γ-secretase 
inhibitors. Leukemia (2006) doi:10.1038/sj.leu.2404258. 
18. Herranz, D. et al. Metabolic reprogramming induces resistance to anti-NOTCH1 
therapies in T cell acute lymphoblastic leukemia. Nat. Med. (2015) 
doi:10.1038/nm.3955. 
19. Cullion, K. et al. Targeting the Notch1 and mTOR pathways in a mouse T-ALL 
model. Blood (2009) doi:10.1182/blood-2008-02-136762. 
20. Ma, W. et al. Notch1 signaling promotes human t-cell acute lymphoblastic 
leukemia initiating cell regeneration in supportive niches. PLoS One (2012) 
doi:10.1371/journal.pone.0039725. 
21. Tatarek, J. et al. Notch1 inhibition targets the leukemia-initiating cells in a 
Tal1/Lmo2 mouse model of T-ALL. Blood (2011) doi:10.1182/blood-2010-08-
300343. 
22. Deangelo, D. J. et al. A phase I clinical trial of the notch inhibitor MK-0752 in 
patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other 
leukemias. J. Clin. Oncol. (2006) doi:10.1200/jco.2006.24.18_suppl.6585. 
23. Papayannidis, C. et al. A Phase 1 study of the novel gamma-secretase inhibitor PF-
03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell 
lymphoblastic lymphoma. Blood Cancer Journal (2015) doi:10.1038/bcj.2015.80. 
24. Girardi, T., Vicente, C., Cools, J. & De Keersmaecker, K. The genetics and 
molecular biology of T-ALL. Blood (2017) doi:10.1182/blood-2016-10-706465. 
25. Tasian, S. K., Teachey, D. T. & Rheingold, S. R. Targeting the PI3K/mTOR 
pathway in pediatric hematologic malignancies. Frontiers in Oncology (2014) 
doi:10.3389/fonc.2014.00108. 
26. Graux, C. et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute 
lymphoblastic leukemia. Nat. Genet. (2004) doi:10.1038/ng1425. 
27. Quintás-Cardama, A. et al. Activity of tyrosine kinase inhibitors against human 
NUP214-ABL1-positive T cell malignancies. Leukemia (2008) 
doi:10.1038/leu.2008.80. 
28. Deenik, W. et al. Rapid complete cytogenetic remission after upfront dasatinib 
monotherapy in a patient with a NUP214-ABL1-positive T-cell acute 
lymphoblastic leukemia. Leukemia (2009) doi:10.1038/leu.2008.318. 
29. Clarke, S., O’Reilly, J., Romeo, G. & Cooney, J. NUP214-ABL1 positive T-cell 
acute lymphoblastic leukemia patient shows an initial favorable response to 
imatinib therapy post relapse. Leukemia Research (2011) 
doi:10.1016/j.leukres.2011.03.025. 
30. Maude, S. L. et al. Efficacy of JAK/STAT pathway inhibition in murine xenograft 
models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood 
(2015) doi:10.1182/blood-2014-06-580480. 
31. Delgado-Martin, C. et al. JAK/STAT pathway inhibition overcomes IL7-induced 
glucocorticoid resistance in a  subset of human T-cell acute lymphoblastic 
leukemias. Leukemia 31, 2568–2576 (2017). 
32. Zhang, Z. Y. Drugging the undruggable: Therapeutic potential of targeting protein 
tyrosine phosphatases. Acc. Chem. Res. (2017) doi:10.1021/acs.accounts.6b00537. 
33. Lazo, J. S. & Sharlow, E. R. Drugging Undruggable Molecular Cancer Targets. 
 
 101 
Annu. Rev. Pharmacol. Toxicol. (2016) doi:10.1146/annurev-pharmtox-010715-
103440. 
34. Wu, Y. L. et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment 
of Asian patients with advanced non-small-cell lung cancer harbouring EGFR 
mutations (LUX-Lung 6): An open-label, randomised phase 3 trial. Lancet Oncol. 
(2014) doi:10.1016/S1470-2045(13)70604-1. 
35. Comert, M., Baran, Y. & Saydam, G. Changes in molecular biology of chronic 
myeloid leukemia in tyrosine kinase inhibitor era. Am. J. Blood Res. (2013). 
36. Lessard, L. et al. PTP1B is an androgen receptor-regulated phosphatase that 
promotes the progression of prostate cancer. Cancer Res. (2012) 
doi:10.1158/0008-5472.CAN-11-2602. 
37. Hoekstra, E. et al. Increased PTP1B expression and phosphatase activity in 
colorectal cancer results in a more invasive phenotype and worse patient outcome. 
Oncotarget (2016) doi:10.18632/oncotarget.7829. 
38. Hu, Z. Q., Li, J., Gao, Q., Wei, S. & Yang, B. SHP2 overexpression enhances the 
invasion and metastasis of ovarian cancer in vitro and in vivo. Onco. Targets. 
Ther. (2017) doi:10.2147/OTT.S138833. 
39. Aceto, N. et al. Tyrosine phosphatase SHP2 promotes breast cancer progression 
and maintains tumor-initiating cells via activation of key transcription factors and 
a positive feedback signaling loop. Nat. Med. (2012) doi:10.1038/nm.2645. 
40. Bessette, D. C., Qiu, D. & Pallen, C. J. PRL PTPs: Mediators and markers of 
cancer progression. Cancer and Metastasis Reviews (2008) doi:10.1007/s10555-
008-9121-3. 
41. Mohn, K. L. et al. The immediate-early growth response in regenerating liver and 
insulin-stimulated H-35 cells: comparison with serum-stimulated 3T3 cells and 
identification of 41 novel immediate-early genes. Mol. Cell. Biol. (1991) 
doi:10.1128/mcb.11.1.381. 
42. Diamond, R. H., Cressman, D. E., Laz, T. M., Abrams, C. S. & Taub, R. PRL-1, a 
unique nuclear protein tyrosine phosphatase, affects cell growth. Mol. Cell. Biol. 
(1994) doi:10.1128/mcb.14.6.3752. 
43. Zeng, Q., Hong, W. & Tan, Y. H. Mouse PRL-2 and PRL-3, two potentially 
prenylated protein tyrosine phosphatases homologous to PRL-1. Biochem. 
Biophys. Res. Commun. (1998) doi:10.1006/bbrc.1998.8291. 
44. Stephens, B. J., Han, H., Gokhale, V. & Von Hoff, D. D. PRL phosphatases as 
potential molecular targets in cancer. Molecular Cancer Therapeutics (2005) 
doi:10.1158/1535-7163.MCT-05-0248. 
45. Rios, P., Li, X. & Köhn, M. Molecular mechanisms of the PRL phosphatases. 
FEBS Journal (2013) doi:10.1111/j.1742-4658.2012.08565.x. 
46. Dumaual, C. M., Sandusky, G. E., Crowell, P. L. & Randall, S. K. Cellular 
localization of PRL-1 and PRL-2 gene expression in normal adult human tissues. 
J. Histochem. Cytochem. (2006) doi:10.1369/jhc.6A7019.2006. 
47. Kozlov, G. et al. Structural Insights into Molecular Function of the Metastasis-
associated Phosphatase PRL-3. J. Biol. Chem. (2004) 
doi:10.1074/jbc.M312905200. 
48. Zhang, H. et al. PRL3 phosphatase active site is required for binding the putative 




49. Guo, K. et al. Catalytic domain of PRL-3 plays an essential role in tumor 
metastasis: Formation of PRL-3 tumors inside the blood vessels. Cancer Biol. 
Ther. (2004) doi:10.4161/cbt.3.10.1111. 
50. Guo, K. et al. Engineering the first chimeric antibody in targeting intracellular 
PRL-3 oncoprotein for cancer therapy in mice. Oncotarget (2012) 
doi:10.18632/oncotarget.442. 
51. Zeng, Q. et al. Prenylation-dependent association of protein-tyrosine phosphatases 
PRL- 1, -2, and -3 with the plasma membrane and the early endosome. J. Biol. 
Chem. (2000) doi:10.1074/jbc.M000453200. 
52. Sun, J. P. et al. Structure and biochemical properties of PRL-1, a phosphatase 
implicated in cell growth, differentiation, and tumor invasion. Biochemistry (2005) 
doi:10.1021/bi0509191. 
53. Saha, S. et al. A phosphatase associated with metastasis of colorectal cancer. 
Science (80-. ). (2001) doi:10.1126/science.1065817. 
54. Kato, H. et al. High expression of PRL-3 promotes cancer cell motility and liver 
metastasis in human colorectal cancer: A predictive molecular marker of 
metachronous liver and lung metastases. Clin. Cancer Res. (2004) 
doi:10.1158/1078-0432.CCR-04-0485. 
55. Hollander, P. Den et al. Phosphatase PTP4A3 promotes triple-negative breast 
cancer growth and predicts poor patient survival. Cancer Res. 76, 1942–1953 
(2016). 
56. Wang, L. et al. Overexpression of phosphatase of regenerating liver-3 in breast 
cancer: Association with a poor clinical outcome. Ann. Oncol. (2006) 
doi:10.1093/annonc/mdl159. 
57. Miskad, U. A., Semba, S., Kato, H. & Yokozaki, H. Expression of PRL-3 
phosphatase in human gastric carcinomas: Close correlation with invasion and 
metastasis. Pathobiology (2004) doi:10.1159/000078671. 
58. Polato, F. et al. PRL-3 phosphatase is implicated in ovarian cancer growth. Clin. 
Cancer Res. (2005) doi:10.1158/1078-0432.CCR-04-2357. 
59. Mayinuer, A. et al. Upregulation of protein tyrosine phosphatase type IVA 
member 3 (PTP4A3/PRL-3) is associated with tumor differentiation and a poor 
prognosis in human hepatocellular carcinoma. Ann. Surg. Oncol. (2013) 
doi:10.1245/s10434-012-2395-2. 
60. Vandsemb, E. N. et al. Phosphatase of regenerating liver 3 (PRL-3) is 
overexpressed in human prostate cancer tissue and promotes growth and 
migration. J. Transl. Med. (2016) doi:10.1186/s12967-016-0830-z. 
61. Ming, J., Liu, N., Gu, Y., Qiu, X. & Wang, E. H. PRL-3 facilitates angiogenesis 
and metastasis by increasing ERK phosphorylation and up-regulating the levels 
and activities of Rho-A/C in lung cancer. Pathology (2009) 
doi:10.1080/00313020802579268. 
62. Qu, S. et al. Independent oncogenic and therapeutic significance of phosphatase 
PRL-3 in FLT3-ITD-negative acute myeloid leukemia. Cancer (2014) 
doi:10.1002/cncr.28668. 
63. Beekman, R. et al. Retroviral integration mutagenesis in mice and comparative 
analysis in human AML identify reduced PTP4A3 expression as a prognostic 
 
 103 
indicator. PLoS One (2011) doi:10.1371/journal.pone.0026537. 
64. Hjort, M. A. et al. Phosphatase of regenerating liver-3 is expressed in acute 
lymphoblastic leukemia and mediates leukemic cell adhesion, migration and drug 
resistance. Oncotarget (2018) doi:10.18632/oncotarget.23186. 
65. Xing, X. et al. Prognostic value of PRL-3 overexpression in early stages of colonic 
cancer. Histopathology (2009) doi:10.1111/j.1365-2559.2009.03226.x. 
66. Radke, I. et al. Expression and prognostic impact of the protein tyrosine 
phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer. Br. J. Cancer (2006) 
doi:10.1038/sj.bjc.6603261. 
67. Xing, X. et al. Phosphatase of regenerating liver-3 (PRL-3) is associated with 
metastasis and poor prognosis in gastric carcinoma. J. Transl. Med. (2013) 
doi:10.1186/1479-5876-11-309. 
68. Dai, N., Lu, A. P., Shou, C. C. & Li, J. Y. Expression of phosphatase regenerating 
liver 3 is an independent prognostic indicator for gastric cancer. World J. 
Gastroenterol. (2009) doi:10.3748/wjg.15.1499. 
69. Ren, T. et al. Prognostic significance of phosphatase of regenerating liver-3 
expression in ovarian cancer. Pathol. Oncol. Res. (2009) doi:10.1007/s12253-009-
9153-1. 
70. Wei, M., Korotkov, K. V. & Blackburn, J. S. Targeting phosphatases of 
regenerating liver (PRLs) in cancer. Pharmacology and Therapeutics (2018) 
doi:10.1016/j.pharmthera.2018.05.014. 
71. Zimmerman, M. W., Homanics, G. E. & Lazo, J. S. Targeted Deletion of the 
Metastasis-Associated Phosphatase Ptp4a3 (PRL-3) Suppresses Murine Colon 
Cancer. PLoS One (2013) doi:10.1371/journal.pone.0058300. 
72. Bardelli, A. et al. PRL-3 Expression in Metastatic Cancers. Clin. Cancer Res. 
(2003). 
73. Parker, B. S. et al. Alterations in vascular gene expression in invasive breast 
carcinoma. Cancer Res. (2004) doi:10.1158/0008-5472.CAN-04-1976. 
74. Rouleau, C. et al. Protein tyrosine phosphatase PRL-3 in malignant cells and 
endothelial cells: Expression and function. Mol. Cancer Ther. (2006) 
doi:10.1158/1535-7163.MCT-05-0289. 
75. Mizuuchi, E., Semba, S., Kodama, Y. & Yokozaki, H. Down-modulation of 
keratin 8 phosphorylation levels by PRL-3 contributes to colorectal carcinoma 
progression. Int. J. Cancer 124, 1802–1810 (2009). 
76. Peng, L. et al. Identification of integrin α1 as an interacting protein of protein 
tyrosine phosphatase PRL-3. Biochem. Biophys. Res. Commun. (2006) 
doi:10.1016/j.bbrc.2006.01.102. 
77. Peng, L. et al. PRL-3 promotes the motility, invasion, and metastasis of LoVo 
colon cancer cells through PRL-3-integrin β1-ERK1/2 and-MMP2 signaling. Mol. 
Cancer 8, (2009). 
78. Zheng, P. et al. Stathmin, a new target of PRL-3 identified by proteomic methods, 
plays a key role in progression and metastasis of colorectal cancer. J. Proteome 
Res. (2010) doi:10.1021/pr100712t. 
79. Liu, Y. et al. PRL-3 promotes epithelial mesenchymal transition by regulating 
cadherin directly. Cancer Biol. Ther. (2009) doi:10.4161/cbt.8.14.8695. 
80. Forte, E. et al. Ezrin is a specific and direct target of protein tyrosine phosphatase 
 
 104 
PRL-3. Biochim. Biophys. Acta - Mol. Cell Res. (2008) 
doi:10.1016/j.bbamcr.2007.11.004. 
81. Orsatti, L. et al. 2-D difference in gel electrophoresis combined with Pro-Q 
Diamond staining: A successful approach for the identification of 
kinase/phosphatase targets. Electrophoresis (2009) doi:10.1002/elps.200800780. 
82. McParland, V. et al. The metastasis-promoting phosphatase PRL-3 shows activity 
toward phosphoinositides. Biochemistry (2011) doi:10.1021/bi201095z. 
83. Gulerez, I. et al. Phosphocysteine in the PRL‑ CNNM pathway mediates 
magnesium homeostasis. EMBO Rep. 17, (2016). 
84. Walls, C. D. et al. Phosphatase of regenerating liver 3 (prl3) provokes a tyrosine 
phosphoproteome to drive prometastatic signal transduction. Mol. Cell. Proteomics 
(2013) doi:10.1074/mcp.M113.028886. 
85. Ellenbroek, S. I. J. & Collard, J. G. Rho GTPases: Functions and association with 
cancer. Clin. Exp. Metastasis (2007) doi:10.1007/s10585-007-9119-1. 
86. Fiordalisi, J. J., Dewar, B. J., Graves, L. M., Madigan, J. P. & Cox, A. D. Src-
Mediated Phosphorylation of the Tyrosine Phosphatase PRL-3 Is Required for 
PRL-3 Promotion of Rho Activation, Motility and Invasion. PLoS One (2013) 
doi:10.1371/journal.pone.0064309. 
87. Krndija, D. et al. The phosphatase of regenerating liver 3 (PRL-3) promotes cell 
migration through Arf-activitydependent stimulation of integrin α5 recycling. J. 
Cell Sci. (2012) doi:10.1242/jcs.104885. 
88. Wang, H. et al. PRL-3 down-regulates PTEN expression and signals through PI3K 
to promote epithelial-mesenchymal transition. Cancer Res. (2007) 
doi:10.1158/0008-5472.CAN-06-3598. 
89. Basak, S. et al. The Metastasis-Associated Gene Prl-3 Is a p53 Target Involved in 
Cell-Cycle Regulation. Mol. Cell (2008) doi:10.1016/j.molcel.2008.04.002. 
90. Guarino, M. Src signaling in cancer invasion. Journal of Cellular Physiology 
(2010) doi:10.1002/jcp.22011. 
91. Liang, F. et al. PRL3 promotes cell invasion and proliferation by down-regulation 
of Csk leading to Src activation. J. Biol. Chem. (2007) 
doi:10.1074/jbc.M608940200. 
92. Dong, J., Sui, L., Wang, Q., Chen, M. & Sun, H. MicroRNA-26a inhibits cell 
proliferation and invasion of cervical cancer cells by targeting protein tyrosine 
phosphatase type IVA 1. Mol. Med. Rep. (2014) doi:10.3892/mmr.2014.2335. 
93. Dumaual, C. M. et al. Tissue-specific alterations of PRL-1 and PRL-2 expression 
in cancer. Am. J. Transl. Res. (2012). 
94. Liu, L. Z. et al. Protein tyrosine phosphatase PTP4A1 promotes proliferation and 
epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma via the 
PI3K/AKT pathway. Oncotarget (2016) doi:10.18632/oncotarget.12116. 
95. Jin, S. et al. Oncogenic function and prognostic significance of protein tyrosine 
phosphatase PRL-1 in hepatocellular carcinoma. Oncotarget (2014) 
doi:10.18632/oncotarget.1986. 
96. Shinmei, S. et al. Identification of PRL1 as a novel diagnostic and therapeutic 
target for castration-resistant prostate cancer by the Escherichia coli ampicillin 




97. Hardy, S. et al. The protein tyrosine phosphatase PRL-2 interacts with the 
magnesium transporter CNNM3 to promote oncogenesis. Oncogene (2015) 
doi:10.1038/onc.2014.33. 
98. Zeng, Q. et al. PRL-3 and PRL-1 promote cell migration, invasion, and metastasis. 
Cancer Res. (2003). 
99. Cates, C. A. et al. Prenylation of oncogenic human PTPcaax protein tyrosine 
phosphatases. Cancer Lett. (1996) doi:10.1016/S0304-3835(96)04459-X. 
100. Hardy, S., Wong, N. N., Muller, W. J., Park, M. & Tremblay, M. L. 
Overexpression of the protein tyrosine phosphatase PRL-2 correlates with breast 
tumor formation and progression. Cancer Res. (2010) doi:10.1158/0008-
5472.CAN-10-2041. 
101. Daouti, S. et al. A selective phosphatase of regenerating liver phosphatase 
inhibitor suppresses tumor cell anchorage-independent growth by a novel 
mechanism involving p130Cas cleavage. Cancer Res. (2008) doi:10.1158/0008-
5472.CAN-07-2349. 
102. McQueeney, K. E. et al. Targeting ovarian cancer and endothelium with an 
allosteric PTP4A3 phosphatase inhibitor. Oncotarget (2018) 
doi:10.18632/oncotarget.23787. 
103. Aguilar-Sopeña, O. et al. Effect of Pharmacological Inhibition of the Catalytic 
Activity of Phosphatases of Regenerating Liver in Early T Cell Receptor Signaling 
Dynamics and IL-2 Production. Int. J. Mol. Sci. 21, 2530 (2020). 
104. McQueeney, K. E. et al. A chemical genetics approach identifies PTP4A3 as a 
regulator of colon cancer cell adhesion. FASEB J. (2018) 
doi:10.1096/fj.201701446R. 
105. Thura, M. et al. PRL3-zumab, a first-in-class humanized antibody for cancer 
therapy. JCI Insight (2016) doi:10.1172/jci.insight.87607. 
106. Thura, M. et al. PRL3-zumab as an immunotherapy to inhibit tumors expressing 
PRL3 oncoprotein. Nat. Commun. (2019) doi:10.1038/s41467-019-10127-x. 
107. Funato, Y. et al. Membrane protein CNNM4-dependent Mg2+ efflux suppresses 
tumor progression. J. Clin. Invest. (2014) doi:10.1172/JCI76614. 
108. Zhan, H. et al. Elevated phosphatase of regenerating liver 3 (PRL-3) promotes 
cytoskeleton reorganization, cell migration and invasion in endometrial stromal 
cells from endometrioma. Hum. Reprod. 31, (2016). 
109. Min, S. H. et al. Downregulation of p53 by phosphatase of regenerating liver 3 is 
mediated by MDM2 and PIRH2. Life Sci. (2010) doi:10.1016/j.lfs.2009.11.010. 
110. Pathak, M. K. et al. Pentamidine is an inhibitor of PRL phosphatases with 
anticancer activity. Mol. Cancer Ther. (2002). 
111. Salamoun, J. M. et al. Photooxygenation of an amino-thienopyridone yields a 
more potent PTP4A3 inhibitor. Org. Biomol. Chem. (2016) 
doi:10.1039/c6ob00946h. 
112. Ahn, J. H. et al. Synthesis and biological evaluation of rhodanine derivatives as 
PRL-3 inhibitors. Bioorganic Med. Chem. Lett. (2006) 
doi:10.1016/j.bmcl.2006.02.060. 
113. Min, G. et al. Rhodanine-based PRL-3 inhibitors blocked the migration and 




114. Hoeger, B., Diether, M., Ballester, P. J. & Köhn, M. Biochemical evaluation of 
virtual screening methods reveals a cell-active inhibitor of the cancer-promoting 
phosphatases of regenerating liver. Eur. J. Med. Chem. (2014) 
doi:10.1016/j.ejmech.2014.08.060. 
115. Bai, Y. et al. Novel anticancer agents based on targeting the trimer interface of the 
PRL phosphatase. Cancer Res. (2016) doi:10.1158/0008-5472.CAN-15-2323. 
116. Wang, L. et al. An anticancer effect of curcumin mediated by down-regulating 
phosphatase of regenerating liver-3 expression on highly metastatic melanoma 
cells. Mol. Pharmacol. (2009) doi:10.1124/mol.109.059105. 
117. Choi, S. K. et al. Biflavonoids inhibited phosphatase of regenerating liver-3 (PRL-
3). Nat. Prod. Res. (2006) doi:10.1080/14786410500463312. 
118. Moon, M. K. et al. Inhibitory activities of anthraquinones from rubia akane on 
phosphatase regenerating liver-3. Arch. Pharm. Res. (2010) doi:10.1007/s12272-
010-1106-4. 
119. Thura, M. et al. PRL3-zumab as an immunotherapy to inhibit tumors expressing 
PRL3 oncoprotein. Nat. Commun. (2019) doi:10.1038/s41467-019-10127-x. 
120. Blackburn, J. S., Liu, S. & Langenau, D. M. Quantifying the frequency of tumor-
propagating cells using limiting dilution cell transplantation in syngeneic 
zebrafish. J. Vis. Exp. (2011) doi:10.3791/2790. 
121. Gürtler, A. et al. Stain-Free technology as a normalization tool in Western blot 
analysis. Anal. Biochem. (2013) doi:10.1016/j.ab.2012.10.010. 
122. Haferlach, T. et al. Clinical utility of microarray-based gene expression profiling 
in the diagnosis and subclassification of leukemia: Report from the international 
microarray innovations in leukemia study group. J. Clin. Oncol. (2010) 
doi:10.1200/JCO.2009.23.4732. 
123. Kohlmann, A. et al. An international standardization programme towards the 
application of gene expression profiling in routine leukaemia diagnostics: The 
Microarray Innovations in LEukemia study prephase. Br. J. Haematol. (2008) 
doi:10.1111/j.1365-2141.2008.07261.x. 
124. Winter, S. S. et al. Identification of genomic classifiers that distinguish induction 
failure in T-lineage acute lymphoblastic leukemia: A report from the Children’s 
Oncology Group. Blood (2007) doi:10.1182/blood-2006-12-059790. 
125. Gutierrez, A. et al. The BCL11B tumor suppressor is mutated across the major 
molecular subtypes of T-cell acute lymphoblastic leukemia. Blood (2011) 
doi:10.1182/blood-2010-11-318873. 
126. Langenau, D. M. et al. Myc-induced T cell leukemia in transgenic zebrafish. 
Science (80-. ). (2003) doi:10.1126/science.1080280. 
127. Li, Z. et al. Inhibition of PRL-3 gene expression in gastric cancer cell line 
SGC7901 via microRNA suppressed reduces peritoneal metastasis. Biochem. 
Biophys. Res. Commun. (2006) doi:10.1016/j.bbrc.2006.07.043. 
128. Qian, F. et al. PRL-3 siRNA inhibits the metastasis of B16-BL6 mouse melanoma 
cells in vitro and in vivo. Mol. Med. (2007) doi:10.2119/2006-00076.Qian. 
129. Buonamici, S. et al. CCR7 signalling as an essential regulator of CNS infiltration 
in T-cell leukaemia. Nature (2009) doi:10.1038/nature08020. 
130. Lin, M. Der et al. Expression of phosphatase of regenerating liver family genes 
during embryogenesis: An evolutionary developmental analysis among 
 
 107 
Drosophila, amphioxus, and zebrafish. BMC Dev. Biol. (2013) doi:10.1186/1471-
213X-13-18. 
131. Wei, M., Haney, M. G., Rivas, D. R. & Blackburn, J. S. Protein tyrosine 
phosphatase 4A3 (PTP4A3/PRL-3) drives migration and progression of T-cell 
acute lymphoblastic leukemia in vitro and in vivo. Oncogenesis (2020) 
doi:10.1038/s41389-020-0192-5. 
132. Cannon, J. L., Oruganti, S. R. & Vidrine, D. W. Molecular regulation of T-ALL 
cell infiltration into the CNS. Oncotarget (2017) doi:10.18632/oncotarget.21394. 
133. Bollu, L. R., Mazumdar, A., Savage, M. I. & Brown, P. H. Molecular pathways: 
Targeting protein tyrosine phosphatases in cancer. Clin. Cancer Res. 23, 2136–
2142 (2017). 
134. Gómez, A. M. et al. Chemokines and relapses in childhood acute lymphoblastic 
leukemia: A role in migration and in resistance to antileukemic drugs. Blood Cells, 
Mol. Dis. (2015) doi:10.1016/j.bcmd.2015.07.001. 
135. Tibes, R. et al. Reverse phase protein array: Validation of a novel proteomic 
technology and utility for analysis of primary leukemia specimens and 
hematopoietic stem cells. Mol. Cancer Ther. (2006) doi:10.1158/1535-7163.MCT-
06-0334. 
136. Okada, M. Regulation of the Src family kinases by Csk. International Journal of 
Biological Sciences (2012) doi:10.7150/ijbs.5141. 
137. Martin, G. S. The hunting of the Src. Nature Reviews Molecular Cell Biology 
(2001) doi:10.1038/35073094. 
138. Zimmerman, M. W. et al. Protein-tyrosine phosphatase 4A3 (PTP4A3) promotes 
vascular endothelial growth factor signaling and enables endothelial cell motility. 
J. Biol. Chem. (2014) doi:10.1074/jbc.M113.480038. 
139. Roux, K. J., Kim, D. I., Raida, M. & Burke, B. A promiscuous biotin ligase fusion 
protein identifies proximal and interacting proteins in mammalian cells. J. Cell 
Biol. (2012) doi:10.1083/jcb.201112098. 
140. Kim, D. I. et al. An improved smaller biotin ligase for BioID proximity labeling. 
Mol. Biol. Cell (2016) doi:10.1091/mbc.E15-12-0844. 
141. Simeoni, L. & Bogeski, I. Redox regulation of T-cell receptor signaling. Biol. 
Chem. 396, 555–569 (2015). 
142. Lo, W. L. et al. Lck promotes Zap70-dependent LAT phosphorylation by bridging 
Zap70 to LAT. Nat. Immunol. (2018) doi:10.1038/s41590-018-0131-1. 
143. Serafin, V. et al. Glucocorticoid resistance is reverted by LCK inhibition in 
pediatric T-cell acute lymphoblastic leukemia. Blood (2017) doi:10.1182/blood-
2017-05-784603. 
144. Serafin, V. et al. Phosphoproteomic analysis reveals hyperactivation of 
mTOR/STAT3 and LCK/Calcineurin axes in pediatric early T-cell precursor ALL. 
Leukemia (2017) doi:10.1038/leu.2017.13. 
 
 108 
                                                                         VITA 
 
Min Wei 
I.  EDUCATION  
University of Kentucky College of Medicine, Lexington, Kentucky          8/2015-current 
       PhD candidate in Molecular and Cellular Biochemistry  
Sun Yat-sen University, Guangzhou, P.R. China                      9/2003-12/2007  
       M.S. in Science specialized in Pharmacology 
Peking University, Beijing, P.R. China                       9/1990-7/1994    
       B.A in Sciences specialized in Pharmaceutical Chemistry 
 
II.   RESEARCH EXPERIENCE 
University of Kentucky, Biochemistry Department, Lexington, KY    05/2016-current 
-Mentor: Jessica Blackburn, PhD 
-Project title: Define the role of protein tyrosine phosphatase 4A3 (PTP4A3 or PRL-    
3) in T cell acute lymphoblastic leukemia. 
University of Kentucky, Markey Cancer Center, Lexington, KY 2/2015-4/2015 
-Mentor: Tianyan Gao, PhD 
-Rotation studying PHLPP function in colon cancer. 
University of Kentucky, Markey Cancer Center, Lexington, KY         11/2014-1/2015 
-Mentor: Kathleen O’Connor, PhD 
-Rotation studying integrin signaling in breast cancer 
University of Kentucky, Markey Cancer Center, Lexington, KY         9/2014-10/2014 
-Mentor: Hunter N. Mosley, PhD 
-Rotation learning Python and Linux 
Massachusetts General Hospital, Transplantation Biology Research center, Boston, MA                                                                                                                    
9/2012-7/2014 
-Mentor: Zhirui Wang, PhD 
-Project title: Development of Diphtheria Toxin (DT) based recombinant 
immunotoxins for transplantation and cancer  
Sun Yat-sen University, Guangzhou, P.R. China                                 12/2005-11/2007 
-Mentor: Liang Tao, PhD 
 
 109 
-Project title: Define the interaction of diazepam with Human T cells and its 
mechanism.  
 
III. AWARDS AND HONORS   
Second place for oral presentation at Biochemistry Department retreat   06/2019 
 
IV. Meetings Attended 
-American Society of Hematology Annual Meeting, Orlando, FL, 2019 (Poster) 
-Midwest Zebrafish Meeting, Lexington, KY, 2019 (poster) 
-University of Kentucky Markey Cancer Center Research Day, Lexington, KY. 
2019 (poster) 
   -Workshop on Frontiers in Phosphatase Research and Drug Discovery, Tokyo,     
Japan, 2018 (Oral and Poster presentation) 
-Protein phosphatase meeting, Snowmass, CO, 2018 (poster) 
-University of Kentucky Markey Cancer Center Research Day, Lexington, KY. 
2018 (poster) 
-American Association of Cancer Research meeting, Chicago, IL. 2018 (poster) 
-University of Kentucky Markey Cancer Center Research Day, Lexington, KY. 
2017 (poster) 
-Experimental Biology 2017, Chicago, IL. 2017 (poster) 
-University of Kentucky Markey Cancer Center Research Day, Lexington, KY. 
2016 
 
V. Peer Reviewed Publications  
1. Wei M, Haney MG, and Blackburn JS. Protein Tyrosine Phosphatase 4A3 
(PTP4A3/PRL-3) drives migration and progression of T-Cell Acute 
Lymphoblastic Leukemia in vitro and in vivo. Oncogenesis, 2020, 9(1):6  
2. Min Wei, Konstantin V. Korotkov, Jessica S. Blackburn. Targeting phosphatase 
of regenerating Liver (PRLs) in Caner. Pharmacology & Therapeutics, 2018 
3. Zhaohui Wang, Min Wei (co-first author), Huiping Zhang, Hongyuan 
Chen, Sharon Germana, Christene A. Huang, Joren C. Madsen,  David H. 
Sachs,  Zhirui Wang. Diphtheria-toxin based anti-human CCR4 immunotoxin for 
targeting human CCR4+ cells in vivo. Molecular Biology, 2015; Vol 9(7): 1458-
1470 
4. Min Wei, Jose Marino, Aaron Trowell, Huiping Zhang, Jaclyn Stromp Peraino, 
Priyani V. Rajasekera, Joren C. Madsen, David H. Sachs, Christene A. Huang, 
Gilles Benichou   and Zhirui Wang. Diphtheria toxin-based recombinant murine 
 
 110 
IL-2 fusion toxin for depleting murine regulatory T cells in vivo. Protein 
Engineering, Design & Selection, 2014; Vol 27 (9): 289 – 29 
5.Jaclyn Peraino, Huiping Zhang, Priyani V. Rajasekera, Min Wei, Joren C.    
Madsena, David H. Sachs, Christene A. Huang, and Zhirui Wang. Diphtheria 
toxin-based bivalent human IL-2 fusion toxin with improved efficacy for 
targeting human CD25+ cells, J Immunol Methods. 2014 March; 405: 57–66. 
         6. Min Wei, Li Li, Rui Meng, Yanying Fan, Yun Liu, Liang Tao, Xianguo Liu, 
Changyou Wu. Suppressive Effect of Diazepam on IFN-γ Production by Human 
T Cells. International Immunopharmacology 10 (2010): 267–271 
 
